Treatment of metastatic pancreatic adenocarcinoma

A combination of BL-8040, pembrolizumab, and chemotherapy agents effectively addresses immunosuppression in metastatic pancreatic adenocarcinoma by enhancing immune cell recruitment and improving clinical responses and survival.

JP2024161518AActive Publication Date: 2024-11-19BIOLINE RX LTD +1
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2024137500
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2018-10-17
Filing Date
2024-08-19
Publication Date
2024-11-19
Estimated Expiration
2039-10-17

AI Technical Summary

Technical Problem

Current treatments for metastatic pancreatic adenocarcinoma, including chemotherapy combinations like gemcitabine and nab-paclitaxel, offer limited survival benefits and are associated with significant side effects, while immunotherapies targeting PD-1/PD-L1 pathways do not effectively overcome immunosuppression in the tumor microenvironment.

Method used

A combination therapy involving the CXCR4 antagonist BL-8040, anti-PD-1 antibody pembrolizumab, and chemotherapy agents such as liposomal irinotecan, fluorouracil, and leucovorin is administered to enhance immune cell recruitment and inhibit immunosuppression, thereby targeting metastatic pancreatic adenocarcinoma.

Benefits of technology

The combination therapy enhances immune cell infiltration into tumors, reduces immunosuppression, and demonstrates improved clinical responses and survival outcomes in patients with metastatic pancreatic adenocarcinoma.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024161518000008
    Figure 2024161518000008
  • Figure 2024161518000001
    Figure 2024161518000001
  • Figure 2024161518000002
    Figure 2024161518000002
Patent Text Reader

Abstract

To provide methods for the treatment of metastatic pancreatic adenocarcinoma and uses of agents.SOLUTION: A method of treating metastatic pancreatic adenocarcinoma in a subject in need thereof is provided. The method comprises administering to the subject a therapeutically effective amount of each of a peptide set forth in a specific sequence, an anti PD-1 and a chemotherapy, thereby treating the metastatic pancreatic adenocarcinoma.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] Related Applications This application is a continuation of U.S. Provisional Patent Application No. 62 / 746,5, filed October 17, 2018. No. 87, the contents of which are incorporated herein by reference in their entirety. This disclosure is incorporated herein by reference.

[0002] Sequence Listing Statement Filed simultaneously with the filing of this application, containing 1018 bytes, October 17, 2019 A file named 78928 Sequence Listing.txt was created on The SCII file is incorporated herein by reference.

[0003] The present invention, in some embodiments thereof, relates to methods and methods for the treatment of metastatic pancreatic adenocarcinoma. and the use of active substances. [Background technology]

[0004] Cancer immunotherapy, a new and rapidly growing field of research, utilizes the body's own immune system in the fight against cancer. Investigating the use of therapies that harness the body's immune system. Tumors have a variety of mechanisms to evade host immune detection. Myeloid-derived suppressor cells (MDSCs), regulatory T cells (Tregs), and Tumor-infiltrating immune cells, such as tumor-associated macrophages, actively regulate the tumor microenvironment. There is mounting evidence that cancer immunotherapy inhibits the effector arm of this response. The aim of the approach is to identify tumors’ ability to suppress detection and elimination by their own host immune system. Several biological mechanisms are being investigated that target a range of immune signaling mechanisms. Substances such as programmed death receptor 1 (PD-1) / programmed death receptor ligand 1 (PD-1) D-L1), lymphocyte activation gene 3 (LAG-3), and killer immunoglobulin-like receptor Several kinase inhibitors (KIRs) are in clinical development for the treatment of various cancers. Part of this is as a result of local immunosuppression mediated by stromal cells (mainly fibroblasts). Activated fibroblasts in the tumor stroma are not responsive to these treatments. It was found to mediate immunosuppression in a mouse cancer model. One suggestion involves the production of the chemokine, CXCL12, by fibroblast stromal cells. Binding of CXCL12 by T cells leads to their exclusion from the vicinity of cancer cells. T cell elimination occurs despite the presence of cancer-specific CD8+ T cells, and is mediated by the T cell checkpoint inhibitor Preclinical studies have demonstrated that this immunosuppression reduces the receptor activity of CXCL12. This is prevented by administration of an inhibitor of the CXC chemokine receptor 4 (CXCR4), which is a receptor for This leads to the rapid accumulation of T cells among cancer cells, thereby inhibiting the immune checkpoint. This demonstrated the unmasking of the efficacy of int inhibitors.

[0005] BL-8040 BL-8040 (formerly named BKT140, SEQ ID NO: 1) is a highly selective CX The investigational drug is a CXCR4 antagonist with high affinity (IC 50 0.5 4-4.5 nM) and inhibits its function. It is a synthetic cyclic peptide of 1000 ribozymes [1]. It is a chemokine that binds to CXCL12 (SDF-1) and is involved in the regulation of stromal CXCR4 and its receptor, CXCR4, mediate the trafficking of hematopoietic cells to the bone marrow (BM). The activity of BL-8040 in various cancer models in mice In addition to its activity as a hematopoietic cell mobilizing factor, animal studies exploring the role of BL-804 0 exerts CXCR4-dependent preferential antitumor activity against CXCR4-overexpressing malignant cells Blocking CXCR4 in vitro and in vivo has been shown to be effective. The efficacy of BL-8040 and its analogues in preventing and treating small cell lung cancer, breast cancer, and malignant tumors has been demonstrated. These include in vitro and in vivo models for human melanoma, neuroblastoma, and pancreatic cancer. As a CXCR4 antagonist, BL- BL-8040 also affects the trafficking of immune cells into the tumor microenvironment. However, natural killer (NK) cells, T cells, and B cells were isolated from the BM and lymph nodes. Using a syngeneic cancer model in mice, B L-8040 removes immunological barriers, allowing the accumulation of immune cells within the tumor microenvironment It has been shown that it can be obtained.

[0006] Preclinical trials The preclinical development of BL-8040 has included numerous pharmacodynamic, pharmacokinetic (PK), safety pharmacology, as well as single and repeated dose toxicity studies.

[0007] BL-8040 inhibits CXCR4-dependent selection of malignant cells both in vivo and in vitro. It exhibits selective cytotoxicity and induces apoptotic cell death in cancer cells [3-6]. 8040 inhibits phosphatidylserine externalization in leukemia and multiple myeloma cells. , reduction in mitochondrial membrane potential, caspase activation, subsequent sub-G1 arrest, and D These effects were shown to be specific; 8040 did not affect the viability of human keratinocytes or normal human hematopoietic cells [3 In addition to its recruitment potential, the nature of this direct apoptotic effect is Distinguishing BL-8040 from other CXCR4 antagonists such as erixafor In addition, administration of BL-8040 increased BM production of NK cells, T cells, and B cells. and induce mobilization from lymph nodes to the surrounding area.

[0008] BL-8040 has demonstrated safety and initial efficacy in several Phase I and II trials. It has shown clinical efficacy [Hidalgo MM, Epelbaum R, Semenisty V, Geva R, Golan T, Borazanci EH. Evaluation of pharmacodynamic (PD) biomarkers in patients with met astatic pancreatic cancer treated with BL-8040, a novel CXCR4 antagonist. J Clin Oncol. 2018; 36:88-88. Abstract].

[0009] Pembrolizumab Pembrolizumab is a potent humanized immunoglobulin that binds to the PD-1 receptor with high specificity. It is an IgG4 monoclonal antibody (mAb) and therefore inhibits PD-1 It inhibits the interaction of PD-L1 and PD-L2 with PD-L1. Based on preclinical in vitro data, Based on these findings, pembrolizumab is a high-affinity and potent receptor blocker for PD-1. Pembrolizumab has an acceptable preclinical safety profile and Keytruda (registered trademark) is currently in clinical development as an IV immunotherapy for advanced malignancies. The drug (pembrolizumab) is indicated for the treatment of patients across several indications.

[0010] Pharmaceutical and Therapeutic Background The importance of an intact immune surveillance mechanism in regulating the growth of neoplastic transformation has been recognized for decades. It has long been known [7]. Accumulating evidence has suggested that tumor-infiltrating lymphocytes and various It has been shown that CD8+ T cells are associated with a favorable prognosis in various malignant tumors. and the ratio of CD8+ effector T cells / FoxP3+ regulatory T cells (Treg) in eggs. solid malignancies such as: malignant, colorectal, and pancreatic cancer; hepatocellular carcinoma; malignant melanoma; and renal cell carcinoma This correlates with improved prognosis and long-term survival in patients with advanced tumours. and reinjection, leading to durable objective tumor responses in cancers such as melanoma. induces [8, 9].

[0011] PD-1 receptor-ligand interactions are hijacked by tumors to suppress immune regulation PD-1 expressed on the cell surface of activated T cells under healthy conditions The normal function of is to downregulate unwanted or excessive immune responses, including autoimmune responses. PD-1 (encoded by the gene Pdcd1) binds its ligand (P Negatively regulates antigen receptor signaling by binding to PD-L1 and / or PD-L2. Cluster of differentiation 28 (CD28) and cytotoxic T-lymphocyte-associated T cells have been shown to A member of the immunoglobulin (Ig) superfamily related to cytoplasmic protein 4 (CTLA-4) bar[10, 11]

[0012] The structure of mouse PD-1 has been elucidated

[12] . PD-1 and its family The members contain Ig variable (IgV) domains responsible for ligand binding and signaling domains. PD-1 is a type I transmembrane glycoprotein that contains a cytoplasmic tail that is responsible for the binding of PD-1 to the cytoplasm. The substrate tail contains two tyrosine-dependent signaling motifs, an immunoreceptor tyrosine-dependent inhibitory Contains an inhibitory motif and an immunoreceptor tyrosine-dependent switch motif. PD-1 binds the tyrosine phosphatases SHP-1 and SHP-2 to its cytoplasmic Recruitment of immune receptor tyrosine-dependent switch motifs within the lateral tail and CD3 T cell signaling CD3 zeta (CD3ζ), protein kinase C-stimulatory receptor (PKC), and PKC-dependent transcription factors are involved in the transcription cascade. effector kinases such as PKCθ, and zeta chain-associated protein kinase 70 (ZAP70). PD-1 downregulates T cell responses, resulting in the dephosphorylation of target molecules [11, 13-15]. The mechanisms underlying this are similar to those of CTLA-4, and both molecules mediate overlapping sets of signaling pathways. They are similar, but different, because they regulate proteins [16, 17]. As such, the PD-1 / PD-L1 pathway is an attractive target for therapeutic intervention in pancreatic cancer. do.

[0013] Preclinical and clinical trials Therapeutic studies in mouse models have demonstrated that it can be used as monotherapy or in combination with other treatment modalities. In combination, administration of an antibody that blocks the PD-1 / PD-L1 interaction enhances tumor-specific CD4 expression. It has been shown that IL-8+ T cell infiltration enhances tumor rejection [18– 23]. Anti-mouse PD-1 antibody or anti-mouse PD-L1 antibody has been used to treat squamous cell carcinoma, pancreatic cancer, and black cell carcinoma. It has shown antitumor responses in models of chromatin deficiency, AML, and colorectal cancer [ 12 , 22 ~25]. In such studies, tumor infiltration by CD8+ T cells and IFN- Increased expression of PD-1, granzyme B, and perforin was observed. The mechanism underlying the antitumor activity of in vivo inhibition of T cell proliferation and activation is localized in vivo. The results showed that the activation of IL-1 expression in syngeneic mouse tumors is involved in the invasion and function of IL-1. Anti-mouse PD-1 antibodies as monotherapy and in combination with chemotherapy in models In vivo efficacy has been confirmed (see Pembrolizumab IB).

[0014] Chemotherapy: Nanoliposomal irinotecan with fluorouracil and leucovorin (Onivyde® with 5-FU / LV) Liposomal irinotecan has the same pharmacologic and clinical limitations as nonliposomal irinotecan. A liposomal formulation of the topoisomerase-1 inhibitor irinotecan was developed to overcome the limitations of 5-FU is indicated for the treatment of patients with pancreatic adenocarcinoma. LV is a chemically reduced derivative of folic acid. It can potentiate the therapeutic and toxic effects of 5-FU. does not appear to alter the plasma pharmacokinetics of 5-FU. It is metabolized to fluorodeoxyuridylic acid, which is then metabolized by the enzyme thymidylate synthase. LV binds to and inhibits ribozyme, an enzyme important in DNA repair and replication. It is easily converted to the original folic acid, 5,10-methylenetetrahydrofolic acid, and its 5,10-methyl Lethylenetetrahydrofolate inhibits the binding of fluorodeoxyuridylate to thymidylate synthase.

[29] IV Lipoproteins act to stabilize the IL-10 receptor, thereby enhancing inhibition of the enzyme. Injectable rinotecan (Onivyde®) is a gemcitabine-based In patients with metastatic pancreatic adenocarcinoma progressing after previous treatment with 5-FU and LV( 5-FU / LV) after gemcitabine-based therapy. A pivotal international phase III NAPO study in patients with progressive metastatic pancreatic adenocarcinoma In the LI-1 trial, liposomal irinotecan in combination with 5-FU / LV Compared with the U / LV control treatment, the primary analysis (after 313 events) and the final analysis (after 38 Median overall survival (OS) (primary endpoint) at time point (after 2 events) The objective response rate (ORR) was also significantly improved. In addition, the liposomal irinotecan + 5-FU / LV group showed significantly higher mean mean scores than the control group. Liposomal irinotecan-based combinations have a manageable safety profile. The most common grade 3 TEAEs were actually hematologic or was the gastrointestinal system [26, 27].

[0015] Treatment indications Pancreatic cancer is a malignant neoplasm of the pancreas with a low early diagnosis rate and poor prognosis. The incidence has increased in recent years, and it now accounts for 1% to 2% of common tumors. Approximately 185,000 people worldwide have been diagnosed with the condition. Its symptoms are usually non-specific. Because of its heterogeneity, pancreatic cancer often goes undiagnosed until it has reached an advanced stage. The only potentially curative treatment is surgical resection. Unfortunately, only 20% of patients Only tumors in the pancreatic cancer group that have undergone resection with negative margins are resectable at the time of diagnosis. Even among those patients who do have a 5-year survival rate of only 10%–25% [30, 31]. The 5-year overall survival rate among patients is less than 5%, the highest among solid malignancies. The overall median survival is less than one year from diagnosis, and with more recent treatments This highlights the need to develop options.

[0016] The anatomy of the pancreas is highly complex. Pancreatic tumors have high interstitial tension and poor blood perfusion. This makes them extremely resistant to most chemotherapy drugs. Conventional systemic IV chemotherapy often fails to achieve effective concentrations. The amount may cause serious adverse reactions and therefore impair the immune system, potentially Clinical treatment failure in patients with pancreatic ductal adenocarcinoma is due to the early metastatic progression. This is due to the high incidence of pulmonary recurrence, high levels of drug resistance to standard treatment options, and high rates of local recurrence. In many cases

[32] .

[0017] Despite recent advances in chemotherapeutic agents and understanding of the molecular biology of pancreatic cancer, metastatic There has been limited progress in the development of treatment options for the disease. Over the past 40 years, several Studies of combination therapy have shown a small survival benefit compared with gemcitabine alone or showed no survival benefit at all. The combination of gemcitabine and erlotinib showed a median survival Gemcitabine monotherapy has been used for several years in metastatic pancreatic cancers until it was shown to increase EGFR levels by 2 weeks. It has been the standard of care for patients with cancer. However, its modest survival benefit However, this was hampered by the significant side effect profile and high cost of treatment. V, 5-FU, irinotecan, and oxaliplatin (FOLFIRINOX) The combination showed an increase in median survival of 4.3 months; however, its side effect profile Considering the file, it is available only to a select group of patients with advanced pancreatic cancer. Recently, the combination of gemcitabine and nab-paclitaxel has shown a median survival time of 1 .8 months and increased 1- and 2-year OS; AEs The clinical features of pulmonary circulation were indicative of pulmonary circulation disorders; they included cytopenias and peripheral neuropathy.

[33] The National Comprehensive Cancer Network's recommendations are Performance status (i.e., ECOG performance status of 0 or 1) For patients with good pain control, patent biliary stents, and adequate nutritional intake, These combinations include FOLFIRINOX, gemcitabine, These include citabine plus nab-paclitaxel, and gemcitabine plus erlotinib. For patients with poor performance status, the only recommended option is In 2015, Onivyde® was developed as a combination therapy with gemcitabine. For patients with metastatic adenocarcinoma of the pancreas in the second-line setting after disease progression following chemotherapy-based therapy First in the US and EU to be used as a chemotherapy agent in combination with 5-FU and LV for the treatment of has been approved [26,34].

[0018] Additional background art includes the following: International Publication No. 2017009843 Brochure International Publication No. 2017009842 Brochure. Summary of the Invention [Means for solving the problem]

[0019] According to aspects of some embodiments of the present invention, there is provided a method for treating metastatic pancreatic adenocarcinoma in a subject in need thereof. 10. A method of treating an inflammatory bowel disease comprising administering to said patient a peptide as set forth in SEQ ID NO:1, anti-PD-1, and chemotherapy. administering a therapeutically effective amount of each to a subject, thereby treating metastatic pancreatic adenocarcinoma. A method is provided that includes:

[0020] According to aspects of some embodiments of the present invention, there is provided a method for treating metastatic pancreatic adenocarcinoma in a subject in need thereof. The peptide set forth in SEQ ID NO: 1, anti-PD-1, and A therapeutically effective amount of each of the therapeutic and chemotherapy agents is provided.

[0021] According to some embodiments of the present invention, a method for treating pancreatic adenocarcinoma is provided. The therapeutic efficacy of the peptide set forth in SEQ ID NO:1, anti-PD-1, and chemotherapy for the treatment of An article of manufacture containing the compound is provided.

[0022] According to some embodiments of the invention, the anti-PD-1 is pembrolizumab.

[0023] According to some embodiments of the invention, the chemotherapy comprises multiple chemotherapeutic agents.

[0024] According to some embodiments of the invention, the chemotherapy is irinotecan, fluorouracil (5-FU), and leucovorin (LV).

[0025] According to some embodiments of the invention, the irinotecan is encapsulated in a liposome.

[0026] According to some embodiments of the invention, irinotecan is administered by Onivyde®. be.

[0027] According to some embodiments of the invention, the peptide is administered subcutaneously (SC).

[0028] According to some embodiments of the invention, the peptide is administered at a dose of 1.25 mg / kg. will be done.

[0029] According to some embodiments of the invention, the anti-PD-1 is administered intravenously (IV).

[0030] According to some embodiments of the invention, the anti-PD-1 is administered at a dose of 200 mg. .

[0031] According to some embodiments of the invention, chemotherapy is administered intravenously.

[0032] According to some embodiments of the invention, the treatment comprises a period of monotherapy with the peptide, followed by These include combination therapies with peptides, anti-PD-1, and chemotherapy.

[0033] According to some embodiments of the invention, the combination chemotherapy and anti-PD-1 therapy is administered for 8 days. It starts in the eyes.

[0034] According to some embodiments of the invention, the combination therapy includes chemotherapy repeated every two weeks. , with anti-PD-1 repeated every 3 weeks.

[0035] According to some embodiments of the present invention, combination therapy with peptides is initiated on day 10. Twice weekly on non-consecutive days, 48 ​​hours apart, at least 24 hours after chemotherapy do.

[0036] According to some embodiments of the invention, monotherapy is administered daily on days 1-5.

[0037] According to some embodiments of the invention, the treatment further comprises an antihistamine, and optionally , including painkillers.

[0038] According to some embodiments of the invention, the combination therapy continues for up to 35 treatments.

[0039] According to some embodiments of the invention, the subject is receiving first-line treatment for metastatic pancreatic adenocarcinoma. Later.

[0040] According to some embodiments of the invention, the first line treatment is a gemcitabine-based chemotherapy. Includes therapy.

[0041] According to some embodiments of the invention, the metastatic pancreatic adenocarcinoma is unresectable.

[0042] According to some embodiments of the invention, the metastatic pancreatic adenocarcinoma is pancreatic ductal adenocarcinoma.

[0043] According to some embodiments of the present invention, the metastatic pancreatic ductal adenocarcinoma is an intraductal papillary mucinous neoplasm. include.

[0044] Unless otherwise specified, all technical and / or scientific terms used herein are , have the same meaning as commonly understood by those of ordinary skill in the art. Methods and materials similar or equivalent to those described herein may be used in the practice or testing of embodiments of the present invention. Exemplary methods and / or materials are described below. The present specification, including definitions, is intended to control. In addition, the materials, methods, and examples are not limited to those described herein. Illustrative only and not necessarily limiting.

[0045] Some embodiments of the invention are herein described, by way of example only, with reference to the accompanying drawings, in which: Reference will now be made in detail and with specificity to the drawings, the particulars thereof being shown by way of example only. It is emphasized that the above is for illustrative purposes only and is intended to discuss embodiments of the present invention. In the drawings, the description given shows how the embodiments of the present invention may be practiced. It will be apparent to one skilled in the art how this can be achieved. [Brief description of the drawings]

[0046] [Figure 1] FIG. 1 illustrates an embodiment of a treatment regimen. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0047] The present invention, in some embodiments thereof, provides methods and compositions for the treatment of pancreatic adenocarcinoma. Regarding substance use.

[0048] Before describing at least one embodiment of the present invention in detail, it is important to note that the present invention may be used in its application. The present invention is not necessarily limited to the details set forth in the following description or illustrated in the examples. It should be understood that the present invention is capable of other embodiments and various modifications. It can be practiced or performed in any manner.

[0049] The present inventors have disclosed a novel method for the treatment of metastatic pancreatic adenocarcinoma in a human subject in need thereof. The clinical protocol was developed through painstaking experimentation and screening.

[0050] Thus, according to an aspect of the present invention, there is provided a method for treating metastatic pancreatic adenocarcinoma in a subject in need thereof. The method comprises administering to the patient a peptide as set forth in SEQ ID NO:1, an anti-PD-1 antibody, and a chemotherapy agent. administering to a subject a therapeutically effective amount of Well, a method is provided.

[0051] According to another aspect of the present invention, there is provided a method for treating metastatic pancreatic adenocarcinoma in a subject in need thereof. The peptide set forth in SEQ ID NO: 1, anti-PD-1, and chemotherapy thereof for use in A therapeutically effective amount of each is provided.

[0052] According to another aspect of the present invention, there is provided a method for the treatment of metastatic pancreatic adenocarcinoma comprising administering to the patient a therapeutically effective amount of a compound of the present invention, ... Therapeutically effective amounts of each of the peptides described in, the anti-PD-1, and the chemotherapy are provided. .

[0053] As used herein, "metastatic pancreatic adenocarcinoma" refers to a tumor that has spread outside of the pancreas, i.e. When present in lymph nodes or other distant locations, this indicates stage IIb to IV disease. vinegar.

[0054] [Table 1-1] [Table 1-2]

[0055] According to certain embodiments, the metastatic pancreatic adenocarcinoma is pancreatic ductal adenocarcinoma.

[0056] As used herein, "pancreatic ductal adenocarcinoma" (PDAC) is a type of exocrine pancreatic cancer. It is made up of cells that line small tubes in the pancreas called ducts (see table above). These cells transport enzyme-containing digestive fluids into the main pancreatic duct and then PDAC can grow anywhere in the pancreas. However, it is mostly found in the head of the pancreas.

[0057] According to certain embodiments, the PDAC comprises intraductal papillary mucinous neoplasm.

[0058] In some embodiments, the pancreatic cancer is recurrent pancreatic cancer.

[0059] In some embodiments, the pancreatic cancer has recurred after going into remission.

[0060] In some embodiments, an individual has a measurable (e.g., by RECIST criteria) have a disease.

[0061] In some embodiments, the individual is diagnosed, e.g., by CT scan (or MRI). , have one or more measurable metastatic tumors.

[0062] In some embodiments, the pancreatic cancer is unresectable pancreatic cancer. In this regard, the pancreatic cancer is resectable pancreatic cancer.

[0063] In some embodiments, the pancreatic cancer is borderline resectable.

[0064] In some embodiments, the primary site of pancreatic cancer is the head of the pancreas. In some embodiments, the primary site of pancreatic cancer is the pancreas body. It occupies the tail of the pancreas.

[0065] As used herein, "subject" refers to a human subject diagnosed with metastatic pancreatic adenocarcinoma. .

[0066] In some embodiments, the subject is a female. In some embodiments, the individual is under about 65 years of age (e.g., under about 60 years of age). Any of the following: under 55 years of age, under 50 years of age, under 45 years of age, or under 40 years of age In some embodiments, the subject is at least about 65 years of age (e.g., at least either about 70 years of age, at least about 75 years of age, or at least about 80 years of age.

[0067] According to certain embodiments, the subject is at least 18 years of age.

[0068] According to certain embodiments, the treatment is after first line treatment for pancreatic adenocarcinoma.

[0069] Thus, the methods, articles, and compositions described herein also provide for the treatment of pancreatic cancer. After failure or substantial failure of prior therapy, or when the pancreatic cancer is amenable to first-line therapy It may be used as a second or third line treatment when the patient is substantially resistant to the treatment. In some embodiments, the individual has pancreatic cancer (e.g., At least one line of therapy (e.g., chemotherapy or In some embodiments, the patient is receiving one line of therapy or had received two lines of treatment (e.g., one line of chemotherapy or immunotherapy). Thus, the treatments described herein can be used as second line treatments. The prior line of treatment may be a prior line of chemotherapy or immunotherapy. may include any of the following: gemcitabine, 5-FU, masitinib, Paclitaxel, trametinib, and / or erlotinib.

[0070] According to certain embodiments, the first line treatment is a gemcitabine-based chemotherapy, in particular For example, gemcitabine under the brand name Gemzar™.

[0071] According to certain embodiments, the disease is treated with first-line, e.g., gemcitabine-based, chemotherapy. Radiographic progression was noted after chemotherapy treatment was discontinued.

[0072] As used herein, the term "treating" refers to preventing the progression of a condition, Qualitatively inhibiting, slowing, or reversing the clinical manifestations of metastatic pancreatic adenocarcinoma The present invention relates to a method for treating a chronic inflammatory bowel disease, including substantially ameliorating the

[0073] According to certain embodiments, the subject has been diagnosed with metastatic pancreatic adenocarcinoma.

[0074] According to certain embodiments, the metastatic pancreatic adenocarcinoma is histologically confirmed (previously (either a previous or new biopsy has been performed).

[0075] According to certain embodiments, the subject is a patient who has met the Response Evaluation Criteria in Solid Tumors. Measurable disease based on Resection Criteria In Solid Tumors (RECIST) v1.1 ( ≥ 1 measurable lesion).

[0076] According to certain embodiments, tumor lesions located in previously irradiated areas are treated with such A lesion is considered measurable if progression has been documented.

[0077] According to certain embodiments, the subject has a histologically confirmed (either previous or new) (biopsy performed in either the pancreatic duct or pancreatic adenocarcinoma) has.

[0078] According to certain embodiments, the pancreatic cancer is acinar cell carcinoma, pancreatoblastoma, malignant cystic tumor, Endocrine neoplasms, squamous cell carcinomas, Vater and periampullary duodenal malignancies nor a common bile duct malignant tumor.

[0079] According to certain embodiments, the subject does not have an intestinal obstruction.

[0080] According to certain embodiments, the subject is not immunocompromised.

[0081] According to certain embodiments, the subject has not received any systemic treatment (i.e. Treatment with disease-modifying drugs, corticosteroids, or immunosuppressants They do not have any serious autoimmune diseases.

[0082] According to certain embodiments, the subject has a history of steroid-requiring (non-infectious) pneumonitis. He does not have any of the current pneumonia.

[0083] According to certain embodiments, the subject has no history of interstitial lung disease.

[0084] As used herein, BL-8040 (previously named "BKT140") The peptide set forth in SEQ ID NO:1, also referred to as , is a novel therapeutic for the treatment of cancer. The peptide binds to CXCR4 with high affinity ( I C 50 0.54-4.5nM) and inhibit its function. A synthetic cyclic peptide of 14 residues was pinned [Tamamura H, Hiramatsu K, Kusano S, Terakubo S, Yamamoto N, Trent JO, et al. Synthesis of potent CXCR4 inhibitors possessing low cytotoxicity and improved biostability based on T140 derivatives Org Biomol Chem 2003;1:3656-3662].

[0085] According to a particular embodiment, BL-8040 is prepared by dissolving in water and 0.45% sodium chloride ( A white to off-white powder of synthetic polypeptide that dissolves easily in 1 / 2 saline solution. It is manufactured by BioConnection BV (formerly MSD ), Kloosterstraat 9, 5349 AB Oss, Netherlan DS is based on the latest Good Manufacturing Practice (cGMP) ) and is manufactured in accordance with the

[0086] PD1 (also known as CD279, programmed death 1) is a member of the Ig gene superfamily. It is a 55 kDa type I transmembrane glycoprotein that is part of the IL-1 receptor and is involved in activated T cells, B cells, and It is expressed on the surface of some immune cells, including NK cells and myeloid cells. 1 binds the membrane-proximal immunoreceptor tyrosine-based inhibitory motif (ITIM) and the membrane-distal tyrosine-dependent It contains an inhibitory switch motif (ITSM).

[0087] The presence of ITIMs on PD-1 suggests that this molecule mediates the anti-PD-1 response by recruiting cytosolic phosphatases. These results suggest that the IL-1 receptor agonists function to attenuate protozoan receptor signaling.

[0088] According to a particular embodiment, the PD1 protein is identified by GenBank number NP_00500. 9. Two ligands for PD-1, P D-L1 and PD-L2 (also known as B7-DC) have been identified.

[0089] The pattern of PD1 expression and function is cell type dependent. PD1 expression is expressed in effector - induced after T cell activation. Upon ligand binding, PD1 binds to the PD-1 receptor, which mediates T cell activation. Inhibits the kinase that regulates the expression of the inhibitory signal, for example through the phosphatase SHP2. Conversely, PD1 is highly expressed on regulatory T cells and mediates the expression of these T cells. In cells, it can enhance the proliferation of regulatory T cells by ligand binding. 1 also induces IL-1 expression in other activated non-T lymphocyte subsets, such as B cells and NK cells. The antibodies are introduced into the host cells, where they exert their antibody production and lytic activity upon ligand binding. Each of these transmits an inhibitory signal that limits the expression of the tumor [Pardoll (2012) Nature Reviews Cancer 12, 252-264].

[0090] As used herein, "anti-PD-1" refers to an antibody that binds PD-1 and inhibits the function of PD-1. The term refers to antibodies that prevent and / or inhibit biological function.

[0091] According to certain embodiments, the PD1 antagonist inhibits PD1-mediated inhibition of immune cells (e.g., Prevent and / or inhibit signaling to T cells, B cells, and NK cells; thereby It inhibits the immunosuppressive activity of PD1.

[0092] The term "antibody" as used in this invention refers to an intact molecule as well as to an antibody that binds to an epitope of an antigen. The present invention includes functional fragments thereof that are capable of binding to the

[0093] As used herein, the term "epitope" refers to the portion of an antigen to which the paratope of an antibody binds. Epitopes are usually antigenic determinants such as amino acids or carbohydrate side chains. A chemically active surface grouping of any molecule, usually characterized by specific three-dimensional structural features and specific It has a charge characteristic of

[0094] According to certain embodiments, the antibody fragment has an ability to bind to an epitope of an antigen in an HLA-restricted manner. single chain, Fab, Fab', and F(ab')2 fragments, Fd, Fca b, Fv, dsFv, scFv, diabody, minibody, nanobody, Fab expression label These include, but are not limited to, libraries, or single domain molecules such as VH and VL. It won't be done.

[0095] Suitable antibody fragments for practicing some embodiments of the present invention include immunoglobulin light receptor agonists (IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-19, IL-20, The complementarity determining regions (CDRs) of the immunoglobulin heavy chain (herein referred to as the "light chain"), The complementarity determining regions of the heavy chain (herein referred to as the "heavy chain"), the variable region of the light chain, the variable region of the heavy chain, Chain, heavy chain, Fd fragment, Fv, single chain Fv (scFv), disulfide stabilized Fv (dsF v) essentially all of both the light and heavy chains, such as Fab, Fab', and F(ab')2 and antibody fragments comprising the variable region of the antibody, or antibody fragments comprising the Fc region of the antibody.

[0096] As used herein, the term "complementarity determining region" or "CDR" refers to a heavy chain Used interchangeably to refer to the antigen-binding region found within the variable region of the light chain polypeptide. Generally, antibodies have three CDRs in each VH (CDR H1 or H 1; CDR H2 or H2; and CDR H3 or H3) and VL There are three CDRs (CDR L1 or L1; CDR L2 or L2; and CDR L3 or L3).

[0097] The identity of the amino acid residues in a particular antibody that make up the variable region or CDR can be determined using methods well known in the art, including the use of Kab (e.g., Kabat et al., 1992, Sequences of Proteins of Immunological Interactions. est, 5th ed., Public Health Service, NIH, Washington DC) The sequence diversity seen in the genomes of 1000-12000 genomes, Chothia et al. (e.g., Chothia et al., Nature 342:877-8 83, 1989.) olecular's AbM antibody modeling software (currently registered with Accelrys Trademark), Martin et al., 1989, Proc. Natl Acad Sci USA. 86:9268; and World (See the Id website at www(dot)bioinf-org(dot)uk / abs) A compromise between Kabat and Chothia using the contact definition possible complex crystal structures (see MacCallum et al., J. Mol. Biol. 262:732-745, 1996); and “Structure definition” (e.g., Makabe et al., Journal of Biological Chemistry, 283:1156-1166, 2008).

[0098] As used herein, "variable region" and "CDR" refer to a combination of approaches. Variable regions and CD4s defined by any approach known in the art, including It may point to R.

[0099] Functional antibody fragments that contain all or essentially all of the variable regions of the light and heavy chains are as follows: It is defined as: (i) Fv, the variable region of the light chain (VL) and the variable region of the heavy chain (V H) is defined as a genetically engineered fragment consisting of; (ii) Single-chain Fv ("scFv"), a single-chain molecule fused to a suitable polypeptide. A genetic variant comprising a light chain variable region and a heavy chain variable region linked by a peptide linker. Child engineered single-stranded molecules; (iii) Disulfide-stabilized Fv ("dsFv"), a genetically engineered disulfide bond A genetically engineered antibody comprising a light chain variable region and a heavy chain variable region linked by ligation. body; (iv) Fab, whole antibody, treated with the enzyme papain to obtain intact light chains, and variable domains of heavy chains. It can be obtained by generating an Fd fragment of the heavy chain consisting of the main and CH1 domains. a fragment of an antibody molecule that contains a monovalent antigen-binding portion of the antibody molecule; (v) Fab', which can be obtained by treating whole antibody with the enzyme pepsin, followed by reduction. (Two Fab' are obtained per antibody molecule) and the antibody molecule binds to a monovalent antigen. a fragment of an antibody molecule containing the binding moiety; (vi) F(ab')2, which can be obtained by treating whole antibody with the enzyme pepsin. A fragment of an antibody molecule (i.e., a fragment of an antibody molecule having two disulfides) that contains a monovalent antigen-binding portion of the antibody molecule. a dimer of Fab' fragments held together by a nucleotide bond); (vii) Single domain antibodies or nanobodies are single domain antibodies that exhibit sufficient affinity for an antigen. composed of one VH or VL domain; and (viii) Fcab, an antigen-binding domain that is formed by introducing antigen-binding capability into the Fc region of an antibody. A fragment of an antibody molecule that contains the Fc portion of the antibody, developed primarily as a mAb.

[0100] Methods for producing polyclonal and monoclonal antibodies, as well as their fragments, are described in , which are well known in the art (see, for example, Harl, ow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, New (see York, 1988).

[0101] An exemplary method for generating antibodies is by inducing in vivo production of antibody molecules, immunoglobulins. Screening of the genomic DNA library (Orlandi DR et al., 1989. Proc. Natl. Acad. Sci. USA 86:3833-3837; Winter G. et al., 1991. Nature 349:293-299), or culture The production of monoclonal antibody molecules by continuous cell lines in culture is carried out using hybrid human B cell hybridoma technology, human B cell hybridoma technology, and Epstein-Barr virus (EBV ) hybridoma technology, but is not limited to it (Kohler G. et al., 1975 . Nature 256:495-497;Kozbor D. et al., 1985. J. Immunol. Methods 81:31-42;Cote RJ. et al., 1983. Proc. Natl. Acad. Sci. USA 80:2026-2030;Cole SP. et al. , 1984. Mol. Cell. Biol. 62:109-120).

[0102] When generating antibodies in vivo, the target antigen must be small enough to elicit a sufficient immunogenic response. In cases where such antigens (haptens) are not available, keyhole limpet hemocyanin (KLH ) or serum albumin [e.g., bovine serum albumin (BSA)] carriers. It can be linked to a neutral carrier (see, for example, U.S. Pat. No. 5,189,178 and (See US Pat. Nos. 5,239,078 and 5,239,078). Linking a hapten to a carrier is well known in the art. For example, direct linkage to an amino group can be achieved using methods well known in the art. and optionally subsequently reducing the imino bond formed. The carrier may be a condensation agent such as dicyclohexylcarbodiimide or other carbodiimide dehydrating agent. Linker compounds may also be used to effect the linkage. Homobifunctional and heterobifunctional linkers are available from Pierce Chemistry. Cal Company, Rockford, Ill. The immunogenic complex can be injected into a suitable mammalian subject, such as a mouse, rabbit, etc. The appropriate protocol is to administer A. japonica following a schedule that boosts antibody production in the serum. The titer of immune serum is determined by repeated injections of the immunogen in the presence of a immunizer. This can be readily determined using well-known immunoassay procedures.

[0103] The antisera obtained can be used directly or monoclonal antibodies can be prepared by the methods described above. It can be obtained as shown.

[0104] Antibody fragments according to some embodiments of the invention may be prepared by proteolytic hydrolysis of the antibody or or fragments thereof in E. coli or mammalian cells (e.g., It can be prepared by Chinese hamster ovary cell culture or other protein expression system. This can be done.

[0105] Antibody fragments can be obtained by pepsin or papain digestion of whole antibodies by conventional methods. For example, antibody fragments can be generated by enzymatic cleavage of antibodies with pepsin. This fragment can be purified by reaction with a thiol reducing agent, and optionally, blocking of the sulfhydryl groups resulting from cleavage of disulfide bonds. It can be further cleaved using a blocking group to produce 3.5S Fab' monovalent fragments. Enzymatic cleavage with pepsin directly produces two monovalent Fab' fragments and an Fc fragment. These methods are described, for example, in Goldenberg, U.S. Pat. Nos. 4,331,647 and 4,331,647, and the references contained therein. No. 6,399,633, which are incorporated herein by reference in their entireties. See also Porter, RR [Biochem. J. 73: 119-126 (1959)]. Separation of the heavy chains to form heavy-chain fragments, further cleavage of the fragments, or other enzymatic or chemical processes. Other methods of fragmenting antibodies, such as chemical or genetic techniques, may also be used to fragment the antibody, provided that the fragment does not contain an intact antibody. As long as it binds to the antigen recognized by the antibody, any may be used.

[0106] As described above, the Fv fragment comprises an association of a VH chain and a VL chain. The case is described in Inbar et al. [Proc. Nat'l Acad. Sci. USA 69:2659-62 (19720)]. Alternatively, the variable chains may be non-covalently linked, such that the variable chains are linked via intermolecular disulfide bonds. They can be linked by bonds or cross-linked by chemicals such as glutaraldehyde. Preferably, the Fv fragment comprises a VH chain and a VL chain connected by a peptide linker. These single-chain antigen-binding proteins (sFv) are linked by oligonucleotides A structural gene comprising DNA sequences encoding the VH and VL domains is constructed. The structural gene is inserted into an expression vector, which is then transformed into a The vector is introduced into a host cell, such as E. coli. The recombinant host cell contains two V domains. To generate sFv, a single polypeptide chain is synthesized containing a linker peptide that bridges the two fragments. Methods for this purpose are described, for example, in Whitlo, w and Filpula, Methods 2: 97-105 (1991);Bird et al., Science 242:423-426 (1988) Pack et al., Bio / Technology 11:1271-77 (1993); and U.S. Pat. No. 4,946,770. This is described in specification No. 78.

[0107] Another form of an antibody fragment is a peptide coding for a single complementarity-determining region (CDR). CDR peptides ("minimal recognition units") are peptides derived from the genes encoding the CDRs of an antibody of interest. Such genes can be obtained by constructing a gene encoding a polymerase Prepared by synthesizing the variable region of an antibody from the RNA of antibody-producing cells using a chain reaction See, e.g., Larrick and Fry, Methods, 2: 106-10 (1991).

[0108] As mentioned, the antibody fragment contains the Fc region of the antibody, termed "Fcab." Such antibody fragments typically contain the CH2-CH3 domains of an antibody. cab is a small molecule that is expressed in the structural loop region of the antibody, i.e., in the CH3 region of the heavy chain. Such antibody fragments are engineered to contain at least one modification, such as, for example, can be made to: contain at least one structural loop region (e.g., an Fc region) A nucleic acid encoding an antibody is provided, comprising at least one nucleic acid sequence encoding at least one structural loop region. The nucleotide residues are modified, the modified nucleic acid is introduced into an expression system, and the modified antibody is expressed. Contacting the modified antibody with the epitope and determining whether the modified antibody binds to the epitope. See, for example, U.S. Patent No. 9,045, which is incorporated herein by reference in its entirety. See specifications 9,133,274 and 9,528.

[0109] Humanized forms of non-human (e.g., murine) antibodies are produced by the synthesis of antibodies that are engineered to contain minimal sequences derived from the non-human immunoglobulin. An immunoglobulin, an immunoglobulin chain, or a fragment thereof (e.g., Fv, F ab, Fab', F(ab').sub.2, or other antigen-binding subsequence of an antibody) A humanized antibody is a chimeric molecule. Humanized antibodies are made by replacing residues from the complementarity determining regions (CDRs) of the recipient. mouse, rat, or rabbit, etc., having the desired specificity, affinity, and capacity. A human immunoglobulin that has been replaced by residues from the CDR (donor antibody) of a non-human species. In some cases, the recipient antibody may contain a human immunoglobulin Fv frame. Humanized antibodies also include those in which the antibody has been modified by a non-human amino acid sequence, such as a nucleotide sequence or a nucleotide sequence. Neither the recipient antibody nor the imported CDR or framework sequences Generally, humanized antibodies contain at least one, and typically two, variable The variable domain may comprise substantially all of the CDR regions. Qualitatively all correspond to those of non-human immunoglobulins, and all or substantially all of their FR regions Humanized antibodies are also optimally characterized as having sequences that are essentially all of human immunoglobulin consensus sequences. , at least a portion of an immunoglobulin constant region (Fc), typically a human immunoglobulin Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature , 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol., 2:593-596 (1992)] .

[0110] Methods for humanizing non-human antibodies are well known in the art. A humanized antibody has one or more amino acid residues introduced into it from a source that is non-human. These non-human amino acid residues are often called import residues, and is typically taken from an import variable domain. Humanization is essentially a process that by substituting one or more CDR sequences of the corresponding sequences of a human antibody. , Winter and co-workers [Jones et al., Nature, 321:522-525 (1986); Riechm ann et al., Nature 332:323-327 (1988);Verhoeyen et al., Science, 239:1534-1536 (1988)]. Thus, such humanized antibodies can be produced according to the methods of Substantially less of an intact human variable domain is provided by the corresponding sequence from a non-human species. It is a chimeric antibody in which the nucleotide sequence is substituted (U.S. Pat. No. 4,816,567). Humanized antibodies typically have some CDR residues and, optionally, some FR residues removed. These are human antibodies in which residues are substituted by residues from analogous sites in rodent antibodies.

[0111] Human antibodies can also be produced using methods known in the art, including phage display libraries. They can be produced using a variety of techniques [Hoogenboom and Winter, J. Mol. Biol., 22 7:381 (1991); Marks et al., J. Mol. Biol., 222:581 (1991)]. Cole et al. and B The technique of Oerner et al. can also be used to prepare human monoclonal antibodies (Cole et al. ., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77 (1985) and Boer ner et al., J. Immunol., 147(1):86-95 (1991)]. Similarly, human antibodies can be produced by human immunoglobulins. Transgenic animals with partial or complete deletion of endogenous immunoglobulin genes. It can be produced by introducing the virus into mice that have already been exposed to the virus or are completely inactivated. In vivo, human antibody production has been observed, which is a process that involves gene rearrangement, assembly, and the expansion of the antibody repertoire. In all respects, including the morphology, this approach is similar to that seen in humans. For example, U.S. Patent Nos. 5,545,807; 5,545,806; Specification No. 69,825; Specification No. 5,625,126; Specification No. 5,633,425 No. 5,661,016, as well as the following scientific publications: Marks et al., Bio / Tech nology 10,: 779-783 (1992);Lonberg et al., Nature 368: 856-859 (1994);Morrison , Nature 368 812-13 (1994);Fishwild et al., Nature Biotechnology 14, 845-51 (19 96);Neuberger, Nature Biotechnology 14: 826 (1996);and Lonberg and Huszar, I Intern. Rev. Immunol. 13, 65-93 (1995).

[0112] Anti-PD1 antibodies suitable for use in the present invention can be prepared using methods well known in the art. , particularly in light of the detailed description set forth above. Anti-PD1 antibodies approved for use in the present invention can be used. Examples of anti-PD1 antibodies include, for example, Topalian, et al. NEJM 2012, US, incorporated herein by reference in its entirety. Patent No. 7,488,802 Specification; No. 8,008,449 Specification; No. 8,609,0 Nos. 89, 6,808,710, 7,521,051, and 816 8757, U.S. Patent Application Publication No. 20140227262; No. 151492; No. 20060210567; and No. 20060034 826, and International Publication No. 2008156712; Brochure No. 089411; Brochure No. 2010036959; Brochure No. 201115 Brochure No. 9877; Brochure No. 2013 / 019906; Brochure No. 2014159 Brochure No. 562; Brochure No. 2011109789; Brochure No. 01 / 14557 Brochure; No. 2004 / 004771 Brochure; and No. 2004 / 0568 This is disclosed in Brochure No. 75.

[0113] Particular anti-PD1 antibodies that can be used in accordance with some embodiments of the invention include: These include, but are not limited to: Nivolumab (also known as MDX1106, BMS-936558, ONO-4538) , marketed by BMY as Opdivo, binds to PD-1 and inhibits the release of PD-1. Blocks activation by PD-L1 and PD-L2. WHO Drug Information , Vol. 27, No. 1, pages 68-69 (2013) ; Pidilizumab (also known as CT-011, hBAT, hBAT-1, (manufactured by Biosciences Inc., Bloomberg) is a humanized monoclonal IgG1 antibody that binds to PD-1. body; AMP-514 (also known as MEDI-0680, and is a 200 mg / kg / day, 20-mg / kg / day, and is a 20-mg ... ne), a humanized monoclonal IgG4 antibody that binds to PD-1; Humanized antibodies h409Al l, h409A16, and h409A17, International Publication No. This is described in brochure No. 08 / 156712.

[0114] According to certain embodiments, the anti-PD-1 is pembrolizumab (MK-3475, Key Also known as Truda, SCH 900475, manufactured by Merck It binds to PD1 and blocks activation of PD1 by its ligand. The structure described in WHO Drug Information, Vol. 27, No. 2, pages 161-162 (2013) It is a humanized monoclonal IgG4 antibody with the structure

[0115] As mentioned, the present teachings contemplate the use of chemotherapy for the treatment of disease. These include gemcitabine, FOLFIRINOX, erlotinib, 5-fluorouracil, and paclitaxel. Clitaxel, nab-paclitaxel, docetaxel, capecitabine, oxaliplatin cisplatin, FOLFOXIRI, Abraxane, anti-CD40 antibody, oregovomab , nelfinavir, cetuximab, tegafur, leucovorin, irinotecan, and These include, but are not limited to, combinations thereof.

[0116] According to certain embodiments, the chemotherapy is a topoisomerase inhibitor, irinotecan. It is.

[0117] Irinotecan is converted by esterase enzymes to the more active metabolite SN-38. The chemical name irinotecan is (S)-4,11-diethyl-3,4,12, 14-Tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[4',4': 6,7]-Indolizino[1,2-b]quinolin-9-yl-[1,4'bipiperidine] Irinotecan hydrochloride trihydrate is also known as CPT-11. and under the trade name CAMPTOSAR®.

[0118] Topoisomerase inhibitors are cyclodextrins or cyclodextrin analogues (e.g. Conjugated with a biocompatible polymer such as sulfonated cyclodextrin For example, the topoisomerase inhibitor may be camptothecin, Chemically conjugated to rinotecan, SN-38, or other topoisomerase 1 inhibitor compounds Cyclodextrin-camptothecin conjugates may be used. Tumor-induced topoisomerase 1 inhibitors were administered weekly at 6 mg / m2, 12 mg / m2, or 18 mg / m2 or every other week at 12 mg / m2, 15 mg / m2, or 18 mg Camptothecin- can be administered in any pharma- ceutically acceptable dose, including at least 100 mg / m2. Cyclodextrin-conjugated topoisomerase 1 inhibitors (e.g., CRLX10 The cyclodextrin-containing polymer conjugate with camptothecin, named “1”, Met) and related intermediates for their preparation are described, for example, in Greenwald et al., Bioorg. Met. d. Chem., 1998, 6, 551-562, and also U.S. Patent Application No. 2010 / 0247668, U.S. US Patent Application No. 2011 / 0160159 and US Patent Application No. 2011 / 01890 This is disclosed in No. 92.

[0119] Topoisomerase inhibitors also include irinotecan, camptothecin, or topotecan. Any liposomal formulation of a topoisomerase inhibitor may be used. For example, MM-398, also known as "nal-IRI," inhibits the cell cycle in tumors. Irinotecan and the active metabolite S A highly stabilized liposomal formulation of irinotecan that provides sustained exposure to N-38. MM-398 is a lipoprotein that has shown promising preclinical and clinical activity in a variety of cancer types. Irinotecan is a serosomal inhibitor of the pancreas after progression on gemcitabine-based therapy. Recently, in the United States, in combination with 5-FU / LV, patients with metastatic adenocarcinoma Compared with free irinotecan, nal-IRI showed a prolonged PK profile. MM-398 and SN-38 have a cytotoxic effect on tumor cell proliferation and secretion, resulting in prolonged local tumor exposure. 38 is cleared more rapidly from normal tissues than from tumors, which is why MM-398 In contrast, delaying veliparib dosing was associated with a predictive window of maximal irinotecan-induced toxicity. It is hypothesized that this would allow veliparib to pass in the absence of concurrent toxicity. However, tumor levels of SN-38 persisted at subsequent time points following veliparib dosing. Therefore, both drugs act simultaneously on the tumor tissue to maintain synergy. maintain the ability to

[0120] One suitable liposomal Top1 inhibitor formulation was previously marketed as MM-3 before FDA approval. 98" under the brand name ONIVYDE (Irinotecan Liposomal Cam Injection (Merrimack Pharmaceuticals, Inc. Liposomal irinotecan, available at Bridge, Mass., and ONIVY It is a liposomal irinotecan product that is bioequivalent to DE. -398 (irinotecan liposome injection) is an intravenous formulation of irinotecan encapsulated in liposomes. It contains irinotecan as the irinotecan sucrose salt. The drug product, liposomes, and forming an aqueous space containing irinotecan in a gelled or precipitated state as a sucrosophate salt. Liposomal membrane vesicles are small unilamellar lipid bilayer vesicles with a diameter of approximately 110 nm that encapsulate the liposome. The gel carrier is 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC). , 6.81 mg / mL; cholesterol, 2.22 mg / mL; and methoxy-terminated poly Ethylene glycol (MW 2000)-distearoylphosphatidylethanolamine The composition is 0.12 mg / mL of 1-methyl-2-propanediol (MPEG-2000-DSPE). 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonyl as a buffer HEPES, 4.05 mg / mL; sodium chloride as an isotonic agent, 8.4 ONIVYDE / MM-398 contains 2 mg / mL of liposomes with a diameter of approximately 100 nm. Approximately 80,000 particles in a gelled or precipitated state as sucrose salt encapsulated in the gel. It is believed to contain the molecule irinotecan.

[0121] Gemcitabine (e.g., Gemzar™) or albumin-bound paclitaxel Kisel (Abraxane), erlotinib (Tarceva), or capecitabine (Xeloda) or in combination with radiation (which Gemcitabine-based chemotherapy, also called chemoradiotherapy.

[0122] As used herein, "leucovorin" is typically used in the preparation of Onivyde (R folinic acid, administered in combination with rituximab (labeled rituximab) and 5-FU.

[0123] 5-FU is a thymidylate synthase (TS) inhibitor. It blocks the action of this enzyme. This means that the synthesis of thymidine, a pyrimidine nucleoside required for DNA replication, is blocked. Thymidylate synthase methylates deoxyuridine monophosphate (dUMP) The administration of 5-FU causes dTMP depletion. This causes rapid division of cancer cells, leading to cell death by thymine starvation. Calcium folinic acid provides an exogenous source of reduced folinic acid salt and therefore , stabilizing the 5-FU-TS complex and therefore enhancing the cytotoxicity of 5-FU. FU is sold under the brand name Adrucil, among others.

[0124] According to certain embodiments, chemotherapy comprises multiple chemotherapeutic agents, e.g., at least two, or at least three, eg, two, three, four, five chemotherapeutic agents.

[0125] According to certain embodiments, chemotherapy includes irinotecan (e.g., liposomally encapsulated Examples include Onivyde®, 5-FU, and leucovorin.

[0126] According to certain embodiments, the treatment does not include oxaliplatin.

[0127] The peptides, antibodies, and chemotherapeutics ("agents") described above may be used by themselves or in combination with other Administered to a subject in a pharmaceutical composition in which it is mixed with a suitable carrier or excipient Each of the agents can be formulated in a separate formulation, or At least some of them may be combined into a single formulation.

[0128] As used herein, a "pharmaceutical composition" refers to a pharmaceutical composition that includes a physiologically suitable carrier and excipient. One or more of the active ingredients described herein, together with any other chemical components. The purpose of a pharmaceutical composition is to facilitate administration of a compound to an organism.

[0129] As used herein, the term "active ingredient" refers to an agent responsible for a biological effect, e.g., a compound. Column number 1, pembrolizumab, irinotecan (e.g., encapsulated in liposomes, e.g. , Onivyde®), 5-FU, and leucovorin.

[0130] Hereinafter, the phrases "physiologically acceptable carrier" and "pharmaceutical acceptable A "carrier suitable for administration" is one that does not cause significant irritation to an organism and is biocompatible with the compound being administered. Adjuvants refer to carriers or diluents that do not abrogate the activity or properties of a substance. Included in.

[0131] As used herein, the term "excipient" refers to an additive or additives added to a pharmaceutical composition to further facilitate administration of an active ingredient. Examples of excipients include, but are not limited to, calcium carbonate, calcium phosphate, calcium, various sugars and various types of starch, cellulose derivatives, gelatin, vegetable oils, and polyethylene glycol.

[0132] Techniques for drug formulation and administration can be found in: “Remington's Pharmaceutical Sciences,” Mack Publishing Co., Easton, PA, lates can be found in the t edition.

[0133] Suitable routes of administration include, for example, oral, rectal, mucosal, particularly nasal, enteral, or parenteral. Oral delivery, e.g., intramuscular, intradermal, subcutaneous, and intramedullary injections, as well as intrathecal and direct intraventricular , for example into the right or left ventricular cavity, into the common coronary artery, intracardially, intravenously, intraperitoneally, intranasally Intraocular or intraocular injections may be included.

[0134] Alternatively, the pharmaceutical composition can be administered in a local rather than systemic manner, e.g., to a tissue region of a patient. Administration may be by injection of the pharmaceutical composition directly into the skin.

[0135] According to a particular embodiment, the peptide of the present invention or a pharmaceutical composition comprising it is administered subcutaneously. will be done.

[0136] According to certain embodiments, an anti-PD-1 antibody (e.g., pembrolizumab) or The pharmaceutical composition comprising the compound is administered intravenously.

[0137] According to certain embodiments, the chemotherapy or pharmaceutical composition comprising same is administered intravenously. .

[0138] The pharmaceutical compositions of some embodiments of the present invention can be prepared by processes well known in the art, For example, conventional mixing, dissolving, granulating, dragee making, gelling, emulsifying, encapsulating, entrapment, Alternatively, it may be prepared using a freeze-drying process.

[0139] Thus, the pharmaceutical compositions for use according to some embodiments of the present invention are pharma- ceutical 1. Contains excipients and auxiliaries that facilitate the processing of the active ingredient into a usable preparation The compositions may be formulated in a conventional manner using one or more physiologically acceptable carriers. The exact formulation will depend on the route of administration chosen.

[0140] Pharmaceutical compositions suitable for use in the context of some embodiments of the present invention include those comprising the active ingredient The composition includes a composition containing the above-mentioned ingredient in an amount effective to achieve the intended purpose. Specifically, according to certain embodiments, the therapeutically effective amount is a dose that is effective to treat a disorder (i.e., metastatic pancreatic adenocarcinoma). The subject in whom the symptoms of By "concentration" is meant an amount of active ingredient effective to prolong survival of the host.

[0141] According to a particular embodiment, the peptide of the present invention or a pharmaceutical composition comprising the same is administered in an amount of 0.1 to 100 mg / ml. Between 10mg / kg body weight, between 0.1-2mg / kg body weight, between 0.1-1mg / kg body weight It is administered at doses ranging from 0.3 to 2, between 0.3 and 10 mg / kg body weight.

[0142] According to a particular embodiment, BL-8040 is administered at a dose of 1-2 mg / kg body weight. do.

[0143] According to a particular embodiment, BL-8040 is administered at a dose of 1.25 to 1.5 mg / kg body weight. It is administered at .

[0144] According to a particular embodiment, BL-8040 is administered at a dose of 1.25 mg / kg body weight. can be.

[0145] According to certain embodiments, BL-8040 is administered subcutaneously (SC).

[0146] According to certain embodiments, anti-PD-1, e.g., pembrolizumab, is administered at a concentration of 0.001 to 3 Between 0 mg / kg body weight, between 0.001 and 20 mg / kg body weight, between 0.001 and 10 mg / Between 0.001 and 1 mg / kg body weight, Between 0.01 and 30 mg / kg body weight , between 0.01 and 20 mg / kg body weight, between 0.01 and 10 mg / kg body weight, between 0.01 and Between 1mg / kg body weight, Between 0.1-30mg / kg body weight, Between 0.1-20mg / kg body weight Between 0.1 and 10 mg / kg body weight Between 0.1 and 5 mg / kg body weight Between 1 and about 30 mg g / kg, 1 to about 20 mg / kg, or 2 to about 10 mg / kg, 0.5 to Between about 30 mg / kg, between 0.5 and about 20 mg / kg, between 0.5 and about 20 mg / kg, The dose ranges from about 1 to about 5 mg / kg, and from about 1 to about 5 mg / kg.

[0147] According to certain embodiments, the anti-PD-1, e.g., pembrolizumab, is administered at a dose of 2.85 mg / mL. It is administered in a dose of 1 kg.

[0148] According to certain embodiments, the anti-PD-1, e.g., pembrolizumab, is administered at a dose of 1 to 500 mg. , 1~400mg, 1~300mg, 1~200mg, 10~500mg, 50~500 100-500 mg, 100-300 mg, or 150-450 mg doses It is given.

[0149] According to certain embodiments, the anti-PD-1 (e.g., pembrolizumab) is administered intravenously (IV ) is administered.

[0150] According to a particular embodiment, the anti-PD-1 is administered at a flat dose of 200 mg.

[0151] According to certain embodiments, chemotherapy is administered intravenously.

[0152] According to certain embodiments, chemotherapy is administered according to tolerated doses known in the art. .

[0153] According to certain embodiments, the dose is Onivyde® 70 mg / m 2 ,B Icovorin 400 mg / m 2 , and fluorouracil 2400 mg / m 2 is .

[0154] The regimen of administration may be as follows: IV Onivyde® over 90 minutes, followed by IV Roy over 30 minutes. Covorin 400mg / m 2 followed by IV fluorouracil 240 for 46 hours. 0 mg / m 2 , once every two weeks.

[0155] According to certain embodiments, the treatment consists of a period of monotherapy with the peptide, followed by a period of monotherapy with the peptide. The present invention includes combination therapy with nivolumab, the anti-PD-1, and the chemotherapy.

[0156] As used herein, "monotherapy" refers to the use of a single drug to treat cancer. The term also includes other medications to treat symptoms not related to the disease itself. For example, analgesics and / or antihistamines, and The use of antiemetic medications and / or antiemetic medications is also considered during monotherapy. During chemotherapy, the use of anticancer drugs (as defined as such) is precluded.

[0157] According to certain embodiments, the duration of monotherapy is up to 7 days.

[0158] According to certain embodiments, the duration of monotherapy is 5 days (eg, daily).

[0159] As used herein, "combination therapy" refers to a combination of This refers to the use of multiple anti-cancer drugs (peptides, chemotherapy, anti-PD-1).

[0160] According to certain embodiments, the chemotherapy and the combination therapy with anti-PD-1 is administered in a 6-1 Starts on day 0.

[0161] According to certain embodiments, the chemotherapy and the combination therapy with PD-1 is administered on day 8. It will begin.

[0162] According to certain embodiments, the combination therapy comprises repeating said chemotherapy every two weeks and administering said anti-cancer drug to a patient. PD-1 is repeated every three weeks.

[0163] According to certain embodiments, the peptide is administered during a monotherapy period, followed by administration of the antibody and Chemotherapy is administered.

[0164] According to a particular embodiment, combination therapy with peptides is initiated on day 10 and separated by 48 hours. Twice weekly on non-consecutive days after chemotherapy (optionally at least 24 hours after chemotherapy) be.

[0165] According to certain embodiments, monotherapy is administered daily on days 1-5.

[0166] Without wishing to be bound by theory, cytotoxic chemotherapy induces tumor death and reduces tumor burden. Cytotoxic chemotherapy induces immunogenic cell death and reduces the This can result in the activation and proliferation of tumor-reactive T cell clones. BL-8040 promotes the infiltration of T cells into the tumor core. C (myeloid-derived suppressor cells) and therefore reduces the immunosuppressive microenvironment. Mubrolizumab maintains / restores the activity of T cells within the tumor.

[0167] Thus, the following are specific embodiments of the invention:

[0168] Pembrolizumab (MK-3475) solution for injection is 100 mg / 4 mL of pembrolizumab. Supplied in single-use Type I glass vials containing izumab (MK-3475) The product is essentially free of extraneous particulates, contains no preservatives, and is a sterile, non-pyrogenic aqueous solution containing This is a solution without

[0169] Chemotherapy: Onivyde® / 5-FU / LV Onivyde is an injection: a white to yellowish opaque liposome in a single-dose vial. The dosage form is 43 mg / 10 mL irinotecan free base as a emulsion dispersion.

[0170] Fluorouracil injection is 2.5g / 50mL (50mg / mL) fluorouracil It is supplied in a pharmacy bulk package as a vial containing

[0171] Leucovorin Calcium for Injection is supplied as a sterile lyophilized powder. The inactive ingredients are sodium chloride per 350 mg vial. Sodium hydroxide and / or hydrochloric acid are added during manufacturing to reduce pH is used to adjust the pH to approximately 8.1. 1 mg of leucovorin calcium is 0. It contains 0.002 mmol of leucovorin and 0.002 mmol of calcium.

[0172] BL-8040 was administered as monotherapy for 5 days starting on day 1 and continuing daily through day 5. The dose is administered by SC injection at 1.25 mg / kg per day. Subjects will receive 1 dose per day in the morning. Received SC injection of BL-8040. Systemic antihistamines with or without painkillers. Premedication with anticoagulants may reduce the risk of local injection site reactions and / or systemic reactions associated with BL-8040. The drug is administered to minimize the occurrence of reactions.

[0173] According to certain embodiments, the BL-8040 injection site is administered to reduce the severity of any local injection site reactions. The dose volume after reconstitution is greater than 2 ml. In some cases, injections will be divided so that each injection is less than 2 ml; At the discretion of the physician, the single dose administration may be divided and injected into more than one site. According to an embodiment, the same instructions apply to concurrent periods of treatment.

[0174] According to certain embodiments, a BL-8040 injection is administered prior to administration of the next BL-8040 injection. A significant increase in measured WBCs (e.g., WBC>60,000 / μL) and / or It would be recognized that if there is evidence of leukostasis, it would be skipped. No signs of stasis and / or a decrease in WBC to ≤60,000 / μL Conditionally, BL-8040 treatment will be resumed.

[0175] Following monotherapy, BL-8040 was administered in combination with pembrolizumab in cycles of 3-week duration, and and as part of a combination treatment with chemotherapy in two-week cycles. According to the dosing, the dosage is as follows:

[0176] During the combination period, BL-8040 should be administered at least 24 hours after chemotherapy, 48 hours apart. The drug is administered as a SC injection in the morning, twice weekly on non-consecutive days.

[0177] Treatment with pembrolizumab begins as part of combination therapy after a period of monotherapy. During the study, pembrolizumab was administered via 30-minute IV infusion on day 1 of each 3-week treatment. According to certain embodiments, pembrolizumab is administered at a dose of 200 mg. For these reasons, it may be administered within 3 days before or after day 1 of each scheduled cycle.

[0178] According to certain embodiments, pembrolizumab is administered at a dose of 200 mg / kg using a 30-minute IV infusion. mg. Given the variability of the infusion pump, the dose is given between -5 and +10 minutes. A window is allowed (i.e., infusion time is 30 min -5 min / +10 min).

[0179] According to certain embodiments, when pembrolizumab is provided on the same day as BL-8040, In this case, BL-8040 was administered 1 hour (±0.5 hours) after the end of the pembrolizumab infusion. It will be recognized that

[0180] According to certain embodiments, when pembrolizumab is provided on the same day as chemotherapy, It is recognized that mubrolizumab should be administered first, followed by chemotherapy. It will be recognized.

[0181] According to certain embodiments, Onivyde is administered prior to LV and 5-FU. Onivyde 70 mg / m as an IV infusion over 90 minutes every 2 weeks 2 ,after that , LV 400mg / m for 30 min 2 IV, followed by 5-FU 2 for 46 hours. 400 mg / m2 IV. UGT1A1 * Patients homozygous for the 28 allele were 50 mg / m 2 Onivyde® at 10 mg / kg / day, and the dose is adjusted at later times (e.g., If tolerated, the dose may be increased at the end of the 35th cycle.

[0182] FIG. 1 illustrates a particular treatment regimen according to an embodiment of the present invention.

[0183] Efficacy testing can be performed at any time during the implementation of a regimen as described herein, e.g. , at least one cycle, two cycles of treatment (e.g., as disclosed in FIG. 1 ); What to do after 3, 5, 10 or more cycles For clarity, cycles can be, for example, 3-week cycles of pembrolizumab. This refers to combination treatment according to the treatment schedule.

[0184] Efficacy Testing Imaging diagnostic evaluation Imaging may be used to assess response. For example, CT or MRI may be used. The same imaging modality should be used throughout treatment for each subject.

[0185] According to certain embodiments, imaging evaluations can be performed at the following time points: Time of subject selection for treatment At the end of the monotherapy period, day 5 At the end of cycle 2 of combination treatment and thereafter for 3 weeks up to 1 year of treatment (cycle 17) Every cycle, and then every 4 cycles until the end of treatment.

[0186] According to certain embodiments, RECIST 1.1 is used for immunotherapeutic treatment. Pembrolizumab and BL-80 are adapted to describe the unique tumor response characteristics of each patient. Agents such as 40 produce antitumor effects by enhancing endogenous cancer-specific immune responses. The response patterns seen with such an approach are similar to those seen with cytotoxic agents, as follows: may extend beyond the typical time course of a response that would be expected to occur after an initial increase in tumor burden or new lesions Clinical responses can be evident even after the appearance of: If radiological imaging confirms initial progressive disease, treatment continues as follows: For this option, tumor evaluation should be repeated after 4 weeks or more to confirm progressive disease. It should be. Repeat imaging shows nadir, stable or improved, previous new Lesions (if identified as the cause of initial progressive disease) and stable / improved non-targeted Less than 20% of the tumor burden compared to the lesion (identified as the initial cause of progressive disease) If there is an increase, treatment may be continued / restarted. Repeated imaging confirms progressive disease according to any of the following scenarios: If so, the subject is discontinued from treatment. - All target lesions in determining whether tumor burden is increasing or decreasing; In addition, non-target lesions are considered.

[0187] Scenarios where progressive disease is confirmed on repeat imaging: Tumor burden still increased by 20% or more compared to nadia and at least 5m remains an absolute increase in m - Non-target lesions that initially caused progressive disease are worsening (qualitative) - New lesions that caused the initial progressive disease are worsening (qualitative) - Additional new lesions since last evaluation

[0188] In subjects with initial evidence of radiologically progressive disease, repeat imaging was obtained. It is at the discretion of the treating physician whether to continue treating the patient until this clinical decision is made. The determination is based on the subject's overall clinical status, including performance status, clinical symptoms, and laboratory data. Subjects should be based on their clinical status as defined by the following criteria: If the patient is clinically stable, they may continue to receive treatment pending confirmation of progressive disease: -No signs or symptoms of disease progression No decrease in ECOG performance status -No rapid progression of the disease Progression in critical anatomical locations (e.g., spinal cord compression) requiring urgent alternative medical intervention No secondary tumors

[0189] If possible, subjects should not be discontinued until progression is confirmed. Initial radiology This tolerance to continue treatment despite progression may allow some subjects to benefit from immunotherapy. During the first few months after initiation, there may be a transient tumor flare, but then there may be a disease response. Subjects considered to be clinically unstable should be monitored for confirmation of progressive disease. Repeated imaging is not required for diagnosis.

[0190] The physician evaluates disease progression and, if the subject is clinically stable (above), the subject is treated. Follow-up imaging should be at least 4 weeks after the first tumor imaging showing progressive disease. At that time, it is at the physician's discretion whether follow-up tumor imaging confirms progressive disease. Investigators will follow irRECIST to determine if progression of disease has occurred. If they meet the conditions detailed above, treatment should be continued until progression is confirmed. This may be followed by regular imaging schedule intervals.

[0191] irRECIST assessment of disease As mentioned above, if tumor imaging shows initial disease progression, the trial Study sites elected to continue treatment by irRECIST and to discontinue treatment at least 4 weeks later. Imaging may be repeated to assess tumor response or documented progression.

[0192] Biopsy analysis According to certain embodiments, a biopsy can be performed at the time of screening, and the gene Tumor mutation burden (TMB), PD-L1, and DNA mismatch repair The patient is evaluated for recovery.

[0193] Blood sampling and processing Samples are collected for safety and efficacy analyses, e.g., CBC, anti-drug antibody titers, and BL-8 040 plasma concentration determination.

[0194] The compositions of some embodiments of the present invention may, if desired, be administered in a single dose containing the active ingredient. or a pack or dispenser, such as an FDA approved kit, which may contain a number of unit dosage forms. The pack may, for example, be a metal foil or plastic pack, such as a blister pack. The pack or dispenser device may comprise a plastic foil. The pack or dispenser may also include instructions for preparation, use, or administration of the pharmaceutical agent. The container may also contain a notice in a form specified by the government agency regulating the sale or sale of the product. The notification reflects approval by the Agency of the composition's form or for human or veterinary administration. Such notices may include, for example, notices approved by the U.S. Food and Drug Administration for prescription drugs. The labeling or approved product insert may be used. Compositions containing the preparations of the present invention may also be prepared as further detailed above. The pharmaceutical composition can be formulated and packaged in an appropriate container and labeled for treatment of an indicated condition.

[0195] As used herein, the term "about" refers to ±10%.

[0196] The terms "comprises", "comprising", "includes", "Including," "having," and their conjugations are "Including, but not limited to."

[0197] The term "consisting of" means "including and limited to."

[0198] The term "consisting essentially of" means that a composition, method, or structure does not contain additional components, steps, and / or parts, provided that additional ingredients, steps, and / or parts are not included. The invention relates to a method for producing a composition, method, or structure that substantially exhibits the basic and novel characteristics of the composition, method, or structure claimed. Only when there is no change.

[0199] As used herein, the singular forms "a," "an," and "the" are used interchangeably. "The" includes plural referents unless the context clearly dictates otherwise. For example, For example, the term "a compound" or "at least one compound" refers to a plurality of compounds, including mixtures thereof. The compound may include:

[0200] Throughout this application, various embodiments of this invention may be presented in a range format. It should be understood that the description in brackets format is merely for convenience and brevity and does not limit the scope of the present invention. It should be understood that the above should not be construed as an indefinite or arbitrary limitation. The description of a range specifically discloses all the possible subranges as well as individual numerical values ​​within that range. For example, a range such as 1 to 6 should be considered as 1 to 3. up to, 1 to 4, 1 to 5, 2 to 4, 2 to 6, 3 to 6, etc. Subranges, plus individual numbers within the range, e.g., 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of its scope. can be.

[0201] Whenever a range of numerical values ​​is given herein, any indicative value within that given range is also included. The term is intended to include any numerical value (fractional or integer) used in a calculation. The phrase "between / between" the indicated number, and the first indicated number The phrase "ranging from" to a second stated number is used herein as a are used interchangeably in the first and second indicated numbers and all fractions in between and integers.

[0202] As used herein, the term "method" refers to a manner or means for accomplishing a given task. refers to the scientific, technical, and methodological fields of chemistry, pharmacology, biology, biochemistry, and medicine. from modes, means, techniques, and procedures known to or by the practitioner of that practice These include methods, means, techniques, and procedures, either readily available or developed. Not limited to.

[0203] Certain features of the invention are described in the context of separate embodiments for clarity. It is recognized that the following may also be provided in combination in a single embodiment. Various features of the invention, which are described in the context of a single embodiment for brevity, may also be or, separately or in any suitable subcombination, or any other described As appropriate in the embodiment, the present invention may be provided. Certain features may be omitted unless the embodiment would be inoperative without those elements. They should not be considered essential features of these embodiments.

[0204] The present invention as described above and as claimed in the claims below. Various embodiments and aspects find experimental support in the following examples. . EXAMPLES

[0205] Reference is made to the following examples, which together with the above descriptions illustrate certain embodiments of the invention. Illustrated in a non-limiting manner.

[0206] [Example 1] the purpose The purpose of this study is to evaluate the efficacy and safety of liposomal irinotecan ( Onivyde® / 5-Fluorouracil / Leucovorin (5-FU / LV) To evaluate the efficacy and safety of BL8040 / pembrolizumab in combination with The mechanism of action of BL-8040 when given alone and in combination was investigated using blood samples and The results will be further studied using human ovarian and tumor tissue samples.

[0207] Study Endpoints Primary Endpoint Response Evaluation Criteria In Solid Tumors (R Objective response rate (ORR) determined according to ECIST v1.1 criteria RECIST1.1 ) Secondary Endpoint Response rate (ORR) determined according to irRECIST criteria irRECIST ) OS PFS Disease Management by RECISIT 1.1 (DC RECIST1.1 ) is a partial response (PR) ), CR, and SD. Safety and Tolerability TEAE Clinical Laboratory Safety Data Vital signs ECG Physical Examination (PE) Overall and early study discontinuation due to AEs explorability Change in tumor marker (CA19-9) from baseline Further tumor tissue analysis

[0208] [Example 2] Study design This is an open-label, single-arm, phase IIa study in patients with metastatic pancreatic adenocarcinoma. The study consisted of two periods: Monotherapy period: 1 week with treatment with BL-8040 on days 1-5 Combination therapy: Onivyde® / 5-FU / LV every 2 weeks, pembrolizumab every 3 weeks once a week, and BL-8040 twice a week.

[0209] Patients with metastatic pancreatic adenocarcinoma progressing after first-line treatment with gemcitabine-based chemotherapy Subjects with BL-8040 will be enrolled and administered 5 days of BL-8040 monotherapy, followed by BL-8040, During the monotherapy period, eligible subjects will receive: Receive SC injections of BL-8040 (1.25 mg / kg) daily on days 1–5.

[0210] Beginning on Day 8, subjects will begin a combination period consisting of: Onivyde® 70mg / m over 90 minutes 2 , then 30 minutes Intermittent IV leucovorin (LV) 400 mg / m 2 , followed by 46 hours of I.V. Fluorouracil (5-FU) 2400mg / m 2 , every 2 weeks Pembrolizumab 200mg once every 3 weeks Starting on day 10, BL-8040 twice weekly and at least 1 day after chemotherapy administration 24 hours later.

[0211] Combination therapy is continued for up to 35 treatments (approximately 2 years) or until progression, clinical deterioration, or The Program will continue until the earlier of the end of the Program or earlier termination, whichever occurs first.

[0212] An independent Data Monitoring Committee (DMC) will administer the study to ensure the welfare of subjects. Serious AEs (SAEs) were consistently reported throughout the study. Be monitored.

[0213] The safety review of the accumulated data of the subjects may have been delayed from the first six subjects to 12 subjects. The subjects (safety dose-limiting toxicity (DLT) cohort) were randomized to receive either monotherapy or combination treatments. Upon completion of 8 days of treatment, safety DLTs will be performed by an independent DMC. The guidelines used by the DMC for the review are set out below: If 0 of 6 subjects experience a DLT during the first cycle of treatment, The combination treatment is deemed eligible for further evaluation and recruitment continues without delay. If 1 of 6 subjects experience a DLT, the safety DLT cohort will This can be expanded to two subjects. If 2 or more of the 6 subjects experience a DLT, the DMC will discontinue the combination treatment. Evaluate the risk / benefit ratio and recommend one or more of the following: 1) Safety DLT considerations The study should be expanded to 12 subjects; 2) the protocol should be amended. 3) the treatment schedule should be modified, or 4) the study should be stopped. It should be. In the expanded safety DLT cohort, ≤2 of 12 subjects experienced DLTs If successful, recruitment may continue up to its proposed full trial size. In the expanded safety DLT cohort, more than 2 of 12 subjects experienced a DLT If a patient experiences a T, the DMC may stop recruitment or amend the protocol. The Board will then decide whether recruitment can continue without any suspension.

[0214] Efficacy data will be assessed throughout the study without stopping recruitment. Review of available data, including imaging, biopsies, and safety evaluations, and The clinical usefulness of the treatment is evaluated.

[0215] [Example 3] Study population Men and women aged 18 years or older with metastatic unresectable PDAC will be enrolled in the trial Inclusion / exclusion criteria were determined based on screening unless otherwise specified within that particular criterion. The evaluation will be carried out during the review period.

[0216] Entry criteria are absolute. Patients who do not meet one or more of the inclusion criteria or who are Any subject who meets one or more of the exclusion criteria will be permitted to enter the study. If a criterion states limits on variables, these limits cannot be exceeded. do not have.

[0217] Inclusion criteria To be eligible to participate in this trial, subjects must meet the following: 1. Age 18 or older 2. Patients must sign a written informed consent prior to entering this study. It must be. 3. Histologically confirmed (either previously or newly biopsied) pancreatic Metastatic unresectable pancreatic adenocarcinoma, including intraductal papillary mucinous neoplasm. 4. Measurable per RECIST v1.1 as determined by site team tumors located in previously irradiated areas Lesions are considered measurable if progression has been documented in such lesions. 5. Previous treatment line Objective radiographic findings after cessation of treatment with first-line gemcitabine-based chemotherapy Progression of pancreatic cancer has been demonstrated. Only patients with primary metastatic disease will be allowed to participate. Patients who had previously undergone surgery for this condition were not permitted to participate. 6. Unless the tumor is deemed inaccessible or otherwise, biopsy is not available to the patient Evaluable pulmonary metastases, preferably from liver metastases, unless otherwise deemed to be in the best interest of the patient and willingness to submit a viable tumor tissue sample. 7. Complete resolution of most recent chemotherapy toxic effects to grade 1 or less (excluding alopecia) If subjects underwent major surgery or >30 Gy of radiation therapy, they were asked to provide a diagnosis of the cause of the intervention. Patients must have recovered from previous toxicities and / or complications. 8.ECOG status ≤ 1 9. Life expectancy of at least 3 months 10. Adequate organ function at baseline as defined below. All clinical tests Surveillance evaluation should be performed within 10 days of initiating treatment. a. Hematology: ·White blood cells (WBC) ≧2,500 / mm 3 Absolute neutrophil count ≥ 1500 / mm 3 ·Platelet count ≧100,000 / mm 3 Hemoglobin ≥ 9g / dL or ≥ 5.6mmol / L Hematocrit ≥ 30% b. Kidney function: Creatinine ≤ 1.5 × upper limit of normal (ULN) or creatinine level > 1.5 × For patients with institutional ULN, measured or calculated creatinine clearance ( Glomerular filtration rate (GFR) can also be used instead of creatinine, and (CrC l)≧60mL / min. c.Liver function: Total bilirubin: Within facility standard range Aspartate aminotransferase / serum glutamate oxaloacetate transaminase Aminotransferase (AST / SGOT) and alanine aminotransferase / serum glutamate Acetylcholinesterase (ALT / SGPT): ≤2.5×ULN, or hepatic ≤ 5 × ULN for subjects with visceral metastases d. Coagulation: INR or PT: ≦1.5×ULN, provided that PT or PTT is within the range of the intended effect of anticoagulant. If the subject is undergoing anticoagulant therapy, as long as it is within the therapeutic range of the prescribed use, except aPTT: ≤ 1.5 × ULN, provided that PT or PTT is within the range of the intended use of anticoagulants As long as the therapeutic range of 11. Subject must use effective contraception: a. Female subjects must be non-childbearing or, if childbearing capable, must be Patients must have a negative urine or serum pregnancy test result within 72 hours prior to ingestion of the substance. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test is required. A serum pregnancy test must be negative for a subject to be eligible. Possible is defined as (non-medical reasons): -Age 45 or older, and have not had a menstrual period for more than two years Amenorrhea for more than 2 years without hysterectomy and oophorectomy, and Follicle-stimulating hormone (FSH) levels within the postmenopausal range as assessed by - Hysterectomy, bilateral oophorectomy, or bilateral fallopian tube dissection at least 6 weeks prior to screening After oral surgery, or bilateral tubal ligation. A documented hysterectomy or oophorectomy was performed after the actual procedure. This must be documented in the medical record or confirmed by ultrasound. The procedure must be verified in the medical record, otherwise the subject will not be Two denominators were administered throughout the study, starting at the time of visit and continuing until 120 days after the last dose of study treatment. The patient must be willing to use appropriate barrier methods. Male subjects will be randomized to receive either the first dose of study treatment or 120 days after the last dose of study treatment. must agree to use an adequate method of contraception until

[0218] Exclusion criteria A subject must be excluded from participation in the trial if: 1. Acinar cell carcinoma, pancreaticoblastoma, malignant cystic neoplasm, endocrine neoplasm, Glandular, including squamous cell carcinoma, Vater and periampullary duodenal or common bile duct malignancies Have a pancreatic tumor other than cancer. 2. Subjects with intestinal obstruction. 3.Having an active infection requiring systemic treatment or having an uncontrolled infection. 4. Have a known additional malignancy that is progressing or requires aggressive treatment. The other is for well-treated basal cell carcinoma or squamous cell carcinoma that has undergone potentially curative treatment. skin cancer, or cervical intraepithelial neoplasia. 5.Having an underlying disease that is expected to prevent participation in the study. 6.Having a disease suitable for treatment administered with curative intent. 7.Currently participating in an investigational drug trial and receiving investigational treatment or in the final stages of treatment Participation, receipt of study treatment, or use of an investigational device within 4 weeks of the first dose There is a saying. 8. Diagnosed with immunodeficiency or taking systemic corticosteroids within 7 days prior to the first dose of study treatment are undergoing chemotherapy or any other type of immunosuppressive therapy. 9. Have received prior anti-cancer monoclonal antibodies (mAbs) within 4 weeks prior to Day 1 of the study or recovered from an AE due to an agent administered >4 weeks prior (i.e., ≤ Grade 1 or at baseline). 10. Prior chemotherapy, targeted small molecule therapy, or radiation within 2 weeks prior to Study Day 1 have received therapy or have recovered from an AE due to a previously administered agent (i.e. ≤ Grade 1 or at baseline). 11. Systemic treatment (i.e., disease-modifying agents, corticosteroids, etc.) within 2 years prior to this study. Active autoimmune disease requiring chemotherapy (steroids, or immunosuppressants). 12. Transfusion or ingestion of blood products (e.g., platelets or red blood cells) within 4 weeks prior to study day 1 or colony-stimulating factors (e.g., granulocyte colony-stimulating factor [G-CSF], GM-CSF , or recombinant erythropoietin). 13. History of steroid-requiring (non-infectious) pneumonitis or current pneumonitis. 14. Have a history of interstitial lung disease. 15. O2 saturation < 92% (on room air). 16. Unstable angina, new-onset angina within the past 3 months, myocardial infarction within the past 6 months, or and current congestive heart failure New York Heart Association Club Class III or higher. Ventricular arrhythmia or control within 6 months prior to study initiation Have poor blood pressure or severe arterial thromboembolism. 17. Any condition, condition or condition that may confound the outcome of this study or prevent a subject from participating in the full duration of this study. Investigators who have past or present evidence of medical or laboratory abnormalities or who are treating In their opinion, it is not in the subjects' best interests to participate. 18. Known psychiatric or substance abuse disorder that would be expected to prevent cooperation with the requirements of this study. has. 19. Treatment outcome starting from the screening visit through 120 days after the last dose of study treatment. Women who are pregnant, breastfeeding, or have children during the planned period of the study Pregnant or expecting to become a father. Tested positive within 72 hours of baseline. Woman with pregnancy test result. 20. Previous treatment with anti-PD-1, anti-PD-L1, or anti-PD-L2 agents or the subject has previously participated in a Merck MK-3475 clinical trial case. 21. Positive HIV test at screening or any time prior to screening Patients without a previous positive HIV test result may not be permitted by local regulations. Have an HIV test at screening unless otherwise advised. 22. Active hepatitis B (positive hepatitis B surface antigen (HBsAg) at screening) ) test result) or Hepatitis C (positive at screening) (defined as having a positive HCV antibody test result or a positive HCV RNA test result) It is used. 23. Known history of chronic hepatitis B or C. 24. Have received a live vaccine within 30 days prior to the planned start of study treatment. Virus-free seasonal influenza vaccines are permitted. 25. Known active central nervous system (CNS) metastases and / or carcinomatous meningitis. Note: Subjects with previously treated brain metastases should be considered if they are stable (first dose of investigational treatment). The same imaging modality, either MRI or MRI, was used for each evaluation for at least 4 weeks prior to the dose. Evidence of progression by imaging using either CT or computed tomography (CT) scans any neurological symptoms have returned to baseline), had no evidence of brain metastases and had not taken steroids for at least 14 days prior to study treatment. This exception applies regardless of clinical stability. This does not include carcinomatous meningitis, which is often caused by 26. Severe hypersensitivity to pembrolizumab and / or any of its excipients (≧grade 3). 27. Have clinical ascites requiring treatment.

[0219] Target Identification Each consented subject will be included in the study from screening until the end of the study or until the subject A unique ID that will be used to identify the subject for all procedures that occur until the completion of this study. Each object is assigned only one object number. The object number is Cannot be reused on a different target.

[0220] Any subjects screened multiple times will be assigned at the first screening visit. A single object may be assigned more than one object number. It is not possible.

[0221] Screening ineligible Subjects who fail to meet the entrance criteria at any stage during the screening period will be , defined as screening ineligible.

[0222] Removal, replacement, or early withdrawal of a subject from treatment or evaluation Subjects were allowed to withdraw from the study at any time point and without prejudice to the administration of further treatment. Patients are free to discontinue the investigational drug and / or their participation in the study. Any subject may be withdrawn if the subject requests to withdraw from the study or if It has been determined that continuation would be expected to result in a significant safety risk to the subject. Patients should be withdrawn from the study if CR is detected early (i.e., within 2 Subjects who discontinue study drug may discontinue study treatment within 1 year of Patients will remain in the study for up to 5 years unless they withdraw their consent to continue participating in the study. Continue to participate in the pursuit.

[0223] Subjects who withdrew from the study before the baseline visit or before the first injection of any of the study medications The elephants are replaced.

[0224] If a subject discontinues the study during the DLT evaluation period for any reason other than safety, the subject will be replaced. Subjects may be enrolled if deemed appropriate to reach the target numbers for DLT evaluation. For subjects who discontinued the study during the DLT period due to progression, a DLT assessment will be considered. however, they will be counted as having progressed for efficacy analyses. Replacements will be assigned a unique procedure / number.

[0225] A subject's use of the study drug may be discontinued for any of the following reasons: ·toxicity ·death · Regulatory agency requirements Sponsor requirements At the request of the primary care physician or investigator: the investigator may withdraw from the study determines that what is in the subject's best interest Withdrawal of consent by the subject ·Disease progression - Women who became pregnant Untraceable Subject does not comply with study procedures / study protocol ·others

[0226] Handling withdrawal If a subject withdraws from the study, every effort will be made to determine the reason. This information will be recorded on the subject's Case Report Form (CRF). All subjects who discontinued for any reason were excluded from all early discontinuation study visits, safety follow-up visits, and follow-up visits. Further, long-term follow-up for survival should be continued.

[0227] If the withdrawal is caused by an AE that the investigator believes may be related to the study drug, If requested, the AE should be reported to the Institutional Review Board / Independent Review Board in accordance with local guidelines. The study will be reported to the ethical committee (IRB / IEC).

[0228] All AEs were prognosticated or stabilized according to the investigator's clinical judgment. All follow-up information will be kept on the CRF of the subject until resolution of the AE. will be recorded.

[0229] Discontinuation of study treatment after CR Discontinuation of study drug may be considered for subjects who achieve a confirmed CR that is: -having been treated with combination therapy for at least 24 weeks, and -Received at least 2 treatment cycles of combination therapy beyond the date of first declared CR .

[0230] [Example 4] Treatment period The treatment period will consist of two periods: · Monotherapy period: BL-8040 will be administered daily on days 1-5. Combination therapy: Chemotherapy: Onivyde® / 5-FU / LV every 2 weeks, Pembrolizumab Mab once every 3 weeks and BL-8040 twice weekly.

[0231] Monotherapy This period begins immediately after baseline, preferably on the day of the baseline assessment, and continues for 1 During this period, BL-8040 is administered daily on days 1-5. Premedication with an antitumor agent may reduce the risk of local injection site reactions and / or systemic reactions associated with BL-8040. Recommended to minimize the occurrence of sexual reactions.

[0232] Week 1 (Days 1-5) Procedure 1. Review of AEs at each visit 2. Premedication and Concomitant Medication 3. Before dosing each day on days 1 to 5 and 4 hours after dosing on days 1 and 5 ( ±2 hours after the initial CBC with differential 4. FAC before and 4 hours (± 2 hours) after administration on days 1 and 5 Blood for immunophenotyping with S. Specific PE on day 5.5 (+ up to 3 days, but before the start of the coadministration period) 6. Vital signs Before administration of BL-8040 on day 5. After administration, the investigator will may be collected by regulation. 7.12 lead ECG CA 19-9 and C at day 8.5 (+ up to 3 days, but before the start of the coadministration period) Blood About EA 9. CXCR before and 4 hours (± 2 hours) after administration on days 1 and 5 Blood for PD-4 and PD-1 expression 10.5 days (+ up to 4 days, but before the start of the combination period) for evaluation from metastasis Tumor tissue collection (biopsy) Tumor imaging assessment on day 11.5 (+ up to 4 days, but before the start of the combination period) Biomarker correlations at day 12.5 (+ up to 3 days, but before start of combination treatment period) Blood for testing of cells, DNA, and RNA Biomarker correlations at day 13.5 (+ up to 3 days, but before the start of the combination period) Serum (immune cells) for testing

[0233] Combination therapy Cycles are defined by a 3-week cycling schedule of pembrolizumab treatment. .

[0234] Beginning on Day 8 (+ up to 4 days), subjects will begin a combination period consisting of treatment with: Onivyde® 70mg / m over 90 minutes 2 , then 30 minutes Intermittent IV LV 400mg / m 2 , followed by IV 5-FU 24 for 46 hours. 00mg / m 2 , every two weeks. · IV pembrolizumab 200mg once every 3 weeks. Starting on day 10, chemotherapy with SC BL-8040 1.25mg / kg, twice weekly At least 24 hours after administration.

[0235] Combination therapy will continue until progression, clinical deterioration, or earlier termination.

[0236] Premedication with a systemic antihistamine has been shown to reduce BL-8040-related local injection site reactions and is recommended to minimize the incidence of pulmonary and / or systemic reactions.

[0237] The following assessments were performed every cycle (time frames are ±3 days unless otherwise specified): It should be: 1. Review of prior and concomitant medications at all visits. 2. Review of AEs at all visits. 3. Starting in Cycle 2, specific PE prior to dosing on Day 1. 4. Vital signs will be assessed before and after study drug administration on Day 1 of each cycle. Vital sign assessments may be collected at the investigator's discretion. 5. Body weight will be assessed at the beginning of each week during the combination treatment period prior to the first injection of that week. BL-8040 doses will be adjusted accordingly. 6. ECOG performance status on Day 1 of each cycle. 7. Pre-study drug chemistry panel on Day 1 of each cycle. 8.Treatment Administration: i.BL-8040 administered twice weekly. ii. Pembrolizumab on day 1 of each 3-week cycle. iii. Onivyde® / 5-FU / LV every 2 weeks.

[0238] The following evaluations are performed on a specific cycle (time frames are ±3 days unless otherwise specified): It should be noted that: 1. CBC Blood Picture with Differential Diagnosis a. Cycle 1: For WBC evaluation, the first three doses of BL-8040 were administered pre-dose (BL-8 040 No time frame is permitted for pre-injection CBC. Further evaluation is deemed necessary. This should be carried out when For WBC evaluation, the first three doses of BL-8040 were administered 4 hours after injection ( ±2 hours) b. Cycle 2 and beyond For WBC evaluation, before each BL-8040 dose in each treatment cycle (BL-8 040 No time frame is permitted for pre-injection CBC. Further evaluation is deemed necessary. This should be carried out when 2. Pre-dose on Day 1 of Cycle 1 and 4 hours (± 2 hours) after combination treatment 2-lead ECG 3. Day 1 of Cycle 1, and then Day 1 of every 2 cycles starting with Cycle 2 Pre-administration T3 (total or free), free T4, and TSH in the eye 4. Pregnancy testing – serum or urine every 2 cycles starting on cycle 2 5. CA 19-9 and CEA on day 1 of every 2 cycles starting in cycle 2 About Blood 6. Blood for immunophenotyping by FACS: Day 15 of cycle 1 and Day 21 of 2 7. CXCR4 and PD- on day 15 of cycle 1 and day 21 of cycle 2 1. Expression of Blood 8. Blood for DNA and RNA for biomarker correlation testing: a. Blood for cell, DNA, and RNA correlation testing was collected at cycle 1 / 2. Day 15 prior to chemotherapy and day 21 of every 2 cycles beginning with cycle 3 Collected in the eye. 9. Tumor imaging assessments at the end of cycle 2 and thereafter for 1 year of treatment (cycle 17) and then every 3 cycles until the end of cycle 34 / termination visit (2-year Treatment is performed every 4 cycles. 10. Serum for biomarker correlation testing was obtained from cycle 1 / 2 chemo On day 15 prior to therapy and on day 21 of every 2 cycles beginning with cycle 3 , collected (immune cells, receptor occupancy, CA 19-9).

[0239] More specific embodiments are outlined below: BL-8040 Treatment with BL-8040 will be daily for 1 week starting on day 1 through day 5 as monotherapy. The subjects received 1.25 mg / kg of DMSO per day by SC injection. Receive a SC injection of BL-8040 in the morning. Systemically, with or without pain medication. Premedication with a selective antihistamine has been shown to reduce the risk of local injection site reactions and / or is recommended to minimize the occurrence of inflammatory or systemic reactions.

[0240] The BL-8040 injection site was If the reconstituted dose volume is greater than 2 ml, the injections will be rotated. should be divided to be less than 2 mL per injection; at the investigator's discretion, The dose may be divided and injected into more than one site. The same instructions are applicable to concurrent studies. This applies to the period of use.

[0241] BL-8040 injections did not significantly increase WBC counts measured before the administration of the next BL-8040 injection. Skip if increased (WBC>60,000 / μL) and / or evidence of leukostasis BL-8040 treatment was performed in patients without signs of leukostasis and / or with WBC values ​​≤ Resume provided there is a reduction to 60,000 / μL.

[0242] Following monotherapy, BL-8040 was administered in combination with pembrolizumab in 3-week cycles. It is administered as part of a treatment regimen as follows: During the combination period, BL-8040 should be administered at least 24 hours after chemotherapy and 48 hours apart. The drug is administered as a SC injection in the morning, twice weekly on non-consecutive days.

[0243] Blood draws and other evaluations should be completed prior to administration of BL-8040. Treatment at 0 will be resumed on the same schedule as defined within the protocol. Provided that it continues in joules, i.e., without making up for missed doses, More than 2 consecutive doses may be skipped during the monotherapy period, or or if more than 3 consecutive doses (1 week of treatment) are skipped during the combination period, The investigator will assess the risks and benefits and decide whether the subject can continue to participate in the study. The reason for discontinuation should be documented in the subject's study record.

[0244] Pembrolizumab Treatment with pembrolizumab begins as part of combination therapy after a period of monotherapy. During this period, pembrolizumab will be administered for each 3-week treatment period after all procedures and evaluations are completed. Administered as a 200 mg dose using a 30 minute IV infusion on Day 1 of ivac Pembrolizumab may be administered for administrative reasons within 3 days before or after day 1 of each scheduled cycle. It may be administered up to

[0245] Pembrolizumab will be administered as a 200 mg dose via 30-minute IV infusion Every effort should be made to aim for injection timing as close to 30 minutes as possible. However, taking into account the variability of the infusion pump, A window of +10 minutes is allowed (i.e., injection time is 30 minutes -5 minutes / +10 minutes). (It is.)

[0246] If pembrolizumab is provided on the same day as BL-8040, BL-8040 administration , 1 hour (± 0.5 hours) after the end of the pembrolizumab infusion. If the drugs are delivered on the same day as chemotherapy, pembrolizumab is administered first, followed by Chemotherapy should be administered.

[0247] Dose interruptions were due to medical / surgical events not related to study treatment or for logistical reasons (i.e. (i.e. elective surgery, unrelated medical events, subject vacation, holidays) are permitted. Patients should be allowed to return to study treatment within 3 weeks of the scheduled interruption. This should be noted in the elephant test records.

[0248] Onivyde / 5-FU / LV Onivyde should be administered prior to LV and 5-FU. Every 2 weeks. Onivyde 70 mg / m as an IV infusion over 90 minutes 2 Then, for 30 minutes, LV 400mg / m 2 IV, followed by 5-FU 2400mg / m for 46 hours. 2 IV. UGT1A1 * Patients homozygous for the 28 allele were randomized to receive Onivyde trademark) at 50mg / m 2 The dose should be increased in subsequent cycles as tolerated. It may be increased if necessary.

[0249] [Example 5] Safety Follow-up Visit After the termination / early termination visit, the safety follow-up visit will be approximately 30 days after the last dose of the last study drug. The test will be performed within 7 days after the start of a new anti-cancer treatment (or within 7 days before the start of a new anti-cancer treatment, whichever comes first). Subjects will be followed up until safety follow-up visit or until resolution of grade 0-1 toxicity or stabilization of AEs. Patients will be monitored for AEs until 90 days after study completion, whichever occurs later. Pregnancy was considered to be within 120 days of the end of the study, and pregnancy was considered to be within 120 days of the end of the study. In either case, if a new anticancer treatment is started, within 30 days of stopping it. If so, it should be reported.

[0250] The following evaluations will be performed during this visit: 1.AE Review 2. Review prior and concomitant medications 3. Anticancer treatment received after the study 4. CBC Blood Picture with Differential Diagnosis 5. Chemical Panel 6. T3 (total or free), free T4, TSH 7.12 lead ECG

[0251] Long-term follow-up of survival All subjects were followed up regardless of the reason for discontinuation (i.e., early termination [ET] or after 2 years). Patients will be contacted by telephone every 12 weeks (± 4 weeks) to assess their vital status. The tracking will continue for up to five years unless they withdraw their consent to continue participating in the study. During these calls, subjects will, among other things, be asked about their disease status and any anti-cancer treatments they have received since the study. All dates must be collected and included in the CRF. is entered.

[0252] Unscheduled visit Unscheduled visits may be made at the subject's request or if deemed necessary by the investigator. Unscheduled visits may occur at any time during the study. The date and reason for any unscheduled visits will be recorded. Monitoring and recording of concurrent medications will be performed by the investigator. and evaluations were completed as deemed necessary by the investigator and included clinical These may include (but are not limited to) safety tests, vital signs, and physical exams. do not have).

[0253] Safety assessment Safety assessments included clinical signs reported by the subjects or observed by the investigator. and based on change from baseline in symptoms, including AEs, concomitant medications, procedures, Compliance, tolerability (e.g., dropout due to AEs), vital signs, E These include CG, physical examination, and laboratory safety assessment.

[0254] Adverse Events (AEs) Adverse events (AEs) will be assessed at all study visits throughout the study.

[0255] Any new AEs occurring between scheduled evaluation visits will be reported to the investigator. The physician should be notified and recorded on the appropriate CRF page in the subject's medical file. do.

[0256] AEs were classified according to the latest National Cancer Institute Common Terminology Criteria for Adverse Events. mmon Terminology Criteria for Adverse Events)(NCI-CTCAE) version( Reported and graded according to the latest version of the Medical Dictionary for Regulatory Activities (MedDRA) It is coded according to the data management used.

[0257] Concomitant drug therapy Use of concomitant medications will be recorded from baseline to all study visits.

[0258] Vital signs, height, and weight Vital signs were assessed at screening, baseline, and day 5 of monotherapy treatment Post-dose assessments will be performed if deemed necessary by the investigator. During the combination period, vital signs were monitored on Day 1 of each cycle. Evaluations will be performed prior to dosing. Further evaluations may be performed at the discretion of the Investigator.

[0259] Vital signs included blood pressure, pulse, oral temperature, and blood pressure after a minimum of 5 minutes of rest, as per standard practice. AEs that met the definition of AEs and were noticed after initiation of study drug Significant findings should be recorded in the AE CRF module.

[0260] Height will be recorded at screening only.

[0261] Body weight was measured at baseline and at the beginning of each week (combination period) after BL-8040 This is recorded prior to administration in order to calculate the dose.

[0262] electro-cardiogram ECGs will be performed at the screening and baseline visits (pre-dose on Day 1). can be.

[0263] During the concomitant period, ECGs were monitored pre-treatment on cycle 1 / day 1 and after the last study drug administration. ECGs will be performed 4 hours (± 2 hours) after administration of the drug. ECGs will also be performed at the termination visit and at and at any safety follow-up visits.

[0264] Additional ECGs will be performed at the discretion of the investigator. Subjects will be You should rest for at least 10 minutes.

[0265] ECG printouts were reviewed, signed, and dated by the investigator or designee. The source documentation file is marked with a date and filed with the possible clinical significance. If the investigator or designee detects any findings that may be related to the outcome, the cardiologist will Advice should be sought regarding the interpretation and, if necessary, appropriate action. Communications and diagnostics should be filed in the source documentation file. The investigator / investigator's designee / local cardiologist must determine whether the ECG findings are consistent with clinical The clinical team is responsible for determining whether any abnormalities are of clinical significance. Clinically significant findings should be reported on the AE CRF page. should be reported to.

[0266] Physical examination and specific physical examination Complete PE will be performed at screening and at the time of discontinuation. PE will include: Assessment of: head and neck, thyroid, respiratory, cardiovascular, ophthalmologic, gastrointestinal, hepatic, and endocrine / metabolic, musculoskeletal, dermatological, lymphatic, neurological, and, where appropriate, study schedule Other body systems as shown in the figure.

[0267] Specific PE was observed on day 5 (± 3 days, but before the first dose of the combination) of the monotherapy period and and from cycle 2 onwards, on the first day of each cycle (± 3 days, except for the first day of During specific PE, A that may be drug-related Focus particular attention on identifying AEs and managing these AEs effectively. It should be.

[0268] There must be information about PE. Significant findings present before study drug initiation. Relevant medical history / current health status must be included in the CRF. Any significant findings occurring after initiation of study drug should be recorded in the AE CRF module. stomach.

[0269] Clinical Laboratory Safety Evaluation All clinical laboratory safety assessments listed below were performed at screening and during specific assessments. Depending on the titer, the antibody titer was determined by local laboratories at different time points during monotherapy and combination treatment. Pre-dose laboratory procedures may be performed within 4 hours prior to dosing.

[0270] Safety clinical laboratory sampling will include the parameters listed below.

[0271] Laboratory tests for hematology, chemistry, urinalysis, and others are specified in Table 2. .

[0272] [Table 2]

[0273] If applicable, serum pregnancy tests will be collected at baseline and performed at a local laboratory. can be.

[0274] Any abnormalities in safety laboratory tests occurring after administration of the study drug should be corrected to normal if clinically necessary. This is repeated until recovery or until the etiology has been determined and the condition is deemed stable. Abnormal laboratory results considered clinically significant by the investigator were considered AEs or CRs. Abnormalities are not considered AEs unless: Not done: Intervention is required A change in dose is needed (reduced, discontinued, or interrupted) Other procedures / treatments are required Associated with other diagnoses

[0275] [Example 6] Efficacy evaluation Imaging diagnostic evaluation Imaging may be used to assess response. For example, CT or MRI may be used. The same imaging modality should be used for each subject throughout treatment.

[0276] According to certain embodiments, imaging assessments can be performed at the following times: Time of subject selection for treatment End of monotherapy period, day 5 At the end of cycle 2 of the combination treatment period and thereafter until the end of one year of treatment (cycle 17) every 3 cycles, and then every 4 cycles until the end of treatment.

[0277] According to certain embodiments, the unique tumor response characteristics observed in response to immunotherapeutic treatment are described. RECIST 1.1 will be applied to clarify the Agents such as 0 may produce antitumor effects by enhancing endogenous cancer-specific immune responses. The response patterns seen with such approaches are similar to those seen with cytotoxic agents. This may extend beyond the time course of a typical response following an initial increase in tumor burden or the development of new lesions. Clinical responses can be elicited even after emergence: If radiological imaging demonstrates initial progressive disease, tumor evaluation is as follows: , with the option to continue treatment, and then follow up at least 4 weeks later to confirm progressive disease. It should be repeated. Repeated imaging may reveal nadirs, stable or improved previous lesions (initial progression) as the cause of progressive disease) and stable / improved non-target lesions (if initially progressive If the tumor burden is less than 20% increased compared to when it was identified as the cause of the disease, , treatment may be continued / restarted. Repeated imaging confirms progressive disease due to any of the scenarios listed below. If so, the subject will discontinue treatment. In determining whether tumor burden increased or decreased, all target lesions, as well as Non-target lesions are considered.

[0278] Scenarios where progressive disease is confirmed on repeat imaging: Tumor burden remains at least 20% greater and at least 5mm greater than nadia It remains an absolute increase. - Non-target lesions that initially caused progressive disease are worsening (qualitative) -New lesions that caused the initial progressive disease are worsening (qualitative) - Additional new lesions since last evaluation

[0279] In subjects with initial evidence of radiologically progressive disease, repeat imaging was obtained. It is at the discretion of the treating physician whether to continue treating the subject until Overall assessment of subjects, including performance status, clinical symptoms, and laboratory data Subjects should be based on their clinical status. Subjects are clinically If clinically stable, patients may continue to receive treatment pending confirmation of progressive disease: -No signs or symptoms of disease progression No decline in ECOG performance status -No rapid progression of the disease In critical anatomical locations (e.g., spinal cord compression) requiring urgent alternative medical intervention No progressive tumors

[0280] If possible, subjects should not be discontinued until progression is confirmed. Initial radiology This tolerance to continue treatment despite progression may allow some subjects to benefit from immunotherapy. During the first few months after initiation, patients may have a transient tumor flare, but then may have a disease response. Subjects considered to be clinically unstable should be monitored for confirmation of progressive disease. Repeated imaging is not required for diagnosis.

[0281] The physician will assess disease progression and, if the subject is clinically stable (above), continue to treat the subject. Imaging should be done at least 4 weeks after the first tumor imaging showing progressive disease. At that time, follow-up tumor imaging confirms progressive disease, at the physician's discretion. Investigators will follow irRECIST to determine progression-free survival. If they meet the conditions detailed above, treatment will continue until progression is confirmed. and may follow regular imaging schedule intervals.

[0282] irRECIST assessment of disease As mentioned above, if tumor imaging shows initial disease progression, the Patients elected to continue treatment and repeat imaging after 4 weeks or more to confirm irRECI Confirmation of tumor response or progression may be assessed by ST.

[0283] Planned biopsy analysis According to certain embodiments, a biopsy can be performed at the time of screening and tumor mutations can be detected. Patients will be assessed for tumor burden (TMB), PD-L1, and DNA mismatch repair status.

[0284] Blood sampling and processing Samples will be collected for safety and efficacy analyses, anti-drug antibody titers, and BL-8040 plasma concentrations. are collected to determine

[0285] [Example 7] Investigational Product Identity BL-8040 BL-8040 is approved by Biokine Thermostat as a novel investigational therapy for the treatment of cancer. Co-developed by apeutics, Ltd. and BioLineRx Ltd. It is a highly selective CXCR4 antagonist.

[0286] BL-8040 is a synthetic polypeptide that is white to off-white in color and is dissolved in water and It is easily soluble in 0.45% sodium chloride (half normal saline). Connection BV (formerly MSD), Kloosterstraat 9 , 5349 AB Oss, Netherlands, the latest Good Manu Manufactured in accordance with current good manufacturing practice (cGMP).

[0287] Pembrolizumab Pembrolizumab (MK-3475) solution for injection is 100 mg / 4 mL of pembrolizumab. Supplied in single-use Type I glass vials containing izumab (MK-3475) The product is essentially free of extraneous particulates, contains no preservatives, and is a sterile, non-pyrogenic aqueous solution containing This is a solution without

[0288] Chemotherapy: Onivyde® / 5-FU / LV Onivyde is an injection: a white to yellowish opaque liposome in a single-dose vial. The dosage form is 43 mg / 10 mL irinotecan free base as a emulsion dispersion.

[0289] Fluorouracil injection is 2.5g / 50mL (50mg / mL) fluorouracil It is supplied in a pharmacy bulk package as a vial containing

[0290] Leucovorin Calcium for Injection is supplied as a sterile lyophilized powder. The inactive ingredients are sodium chloride per 350 mg vial. Sodium hydroxide and / or hydrochloric acid are added during manufacturing to reduce pH is used to adjust the pH to approximately 8.1. 1 mg of leucovorin calcium is 0. It contains 0.002 mmol of leucovorin and 0.002 mmol of calcium.

[0291] [Example 8] Pembrolizumab and chemotherapy in patients with metastatic pancreatic adenocarcinoma (PDAC) Phase 2a study to evaluate the safety and efficacy of BL-8040 in combination background Current treatment options for PDAC are limited. Although these drugs have shown promising results in other cancer types, this approach has not been shown to be effective in PDAC. In cohort 1 of the COMBAT study, BL-8040 (CXCR The dual combination of 4 inhibitors and pembrolizumab was safe and effective in second-line (2L) patients. showed a promising median overall survival (OS) of 7.5 months in patients with refractory glaucoma (Hidalgo, A., et al., AP hase 2a Trial to Assess the Safety and Efficacy of BL-8040 and Pembrolizumab in Patients with Metastatic Pancreatic Adenocarcinoma (PDAC). Annals of Oncology, 2 BL-8040 is an efficacious cell line that expresses granzyme B. In addition, by increasing the levels of myeloid-derived suppressor cells (MDS C) to modify the tumor microenvironment (TME).

[0292] These encouraging results, along with the combination of BL-8040, pembrolizumab, and chemotherapy, Based on preclinical data supporting the combination of BL-8040, pembrolizumab, The combination group (cohort) consisted of mab and chemotherapy (Onivyde / 5-FU / LV). The preclinical efficacy of BL-8040 in this expanded cohort was expanded to include Efficacy and safety data are provided below.

[0293] method Phase 2a study, cohort 2, treatment regimen consisted of 5 days of BL-8040 monotherapy, Then, Onivyde / 5-FU / LV every 2 weeks, pembrolizumab every 3 weeks, and The study consisted of combination treatment with gemcitabine-based chemotherapy and BL-8040 twice weekly. Progressing after first-line chemotherapy treatment, measurable disease as described in Example 3 The present invention includes metastatic PDAC subjects with disease for which treatment is feasible.

[0294] result As of September 2019, 22 patients have been enrolled, of which 15 are evaluable. (i.e., received at least one dose of the combination and had a post-baseline CT). Median age 68 years, ECOG ≤ 1, and 60% male. 15 SAEs were reported by 10 patients. Two subjects discontinued due to SAEs. RE for the evaluable population The best responses with CISTv1.1 (Example 6) were 4 partial responses (PR) and 8 Patients with stable disease (SD), a total of 12 subjects with disease control out of 15 The median PFS and OS had not yet been reached. In particular, SD and PR All patients with CA 19-9 had an initial increase, followed by a decrease. began during a transient increase in CA 19-9.

[0295] conclusion Ongoing COMB with triple combination of BL-8040, pembrolizumab, and chemotherapy Preliminary data from AT cohort 2 showed encouraging overall response rate (ORR) (4 / 15) and The disease control rate (DCR) (12 / 15) is shown.

[0296] While the invention has been described in conjunction with specific embodiments thereof, many alternatives, modifications, and variations are possible. It is apparent that variations will be apparent to those skilled in the art. All such alternatives, modifications, and variations falling within the spirit and broad scope of the This is intended to encompass all such options.

[0297] All publications, patents, and patent applications mentioned in this specification are hereby incorporated by reference as if each individual publication were incorporated by reference in its entirety. All publications, patents, or patent applications are specifically and individually indicated to be incorporated by reference herein. No. 6,313,635, filed on Oct. 13, 2006. The present invention is incorporated by reference in its entirety to the same extent as if set forth herein. Additionally, citation or identification of any reference in this application constitutes acceptance of such reference. Nothing herein should be construed as an admission that any reference is available as prior art to the present invention. To the extent section headings are used, they are not necessarily to be construed as limiting. You shouldn't.

[0298] Additionally, any priority documents to this application are incorporated herein by reference in their entirety. It is being done.

[0299] [Table 3-1]

[0300] [Table 3-2]

[0301] [Table 3-3]

[0302] [Table 3-4]

Claims

1. 1. A method of treating metastatic pancreatic adenocarcinoma in a subject in need thereof, comprising administering to a subject a compound as set forth in SEQ ID NO:

1. A therapeutically effective amount of each of the peptide, the anti-PD-1, and the chemotherapy is administered to the subject. thereby treating the metastatic pancreatic adenocarcinoma.

2. For use in treating metastatic pancreatic adenocarcinoma in a subject in need thereof, the method comprises administering to the subject a compound of the present invention comprising ... Therapeutically effective amounts of each of the peptides described in No. 1, anti-PD-1, and chemotherapy.

3. A peptide according to SEQ ID NO: 1, an anti-PD-L1 antibody, for use in the treatment of metastatic pancreatic adenocarcinoma. 1, and a therapeutically effective amount of each of chemotherapy.

4. The method of any one of claims 1 to 3, wherein the anti-PD-1 is pembrolizumab. or a therapeutically effective amount or article of manufacture.

5. The method according to any one of claims 1 to 4, wherein the chemotherapy comprises multiple chemotherapeutic agents. or a therapeutically effective amount or product.

6. The chemotherapy comprises irinotecan, fluorouracil (5-FU), and leucovorin. The method or therapeutically effective amount or product according to any one of claims 1 to 5, comprising (LV). Manufactured item.

7. The method according to any one of claims 1 to 6, wherein the irinotecan is encapsulated in a liposome. A method or a therapeutically effective amount or article of manufacture.

8. 8. Any one of claims 1 to 7, wherein the irinotecan is Onivyde®. A method or a therapeutically effective amount or article of manufacture according to claim 1.

9. The method according to any one of claims 1 to 8, wherein the peptide is administered subcutaneously (SC). or a therapeutically effective amount or article of manufacture.

10. 10. The method of claim 1, wherein the peptide is administered at a dose of 1.25 mg / kg.

2. A method or a therapeutically effective amount thereof.

11. The method according to any one of claims 1 to 10, wherein the anti-PD-1 is administered intravenously (IV). or a therapeutically effective amount.

12. The method according to any one of claims 1 to 11, wherein the anti-PD-1 is administered at a dose of 200 mg. The method or therapeutically effective amount thereof.

13. The method according to any one of claims 1 to 12, wherein the chemotherapy is administered intravenously. is a therapeutically effective dose.

14. The treatment comprises a period of monotherapy with the peptide, followed by a period of treatment with the peptide, the anti-PD -1, and a combination therapy with said chemotherapy according to any one of claims 1 to 13. Method or therapeutically effective amount.

15. 1, wherein the chemotherapy and the combination therapy with anti-PD-1 are initiated on day 8.

15. A method or a therapeutically effective amount according to any one of claims 1 to 14.

16. The combination therapy comprises repeating the chemotherapy every 2 weeks and the anti-PD-1 every 3 weeks.

16. The method or therapeutically effective amount of claim 14 or 15, wherein the

17. The combination therapy with the peptides was started on day 10, and administered in non-consecutive doses 48 hours apart.

16. The method or therapeutically effective amount of claim 15, wherein the administration is twice weekly on a daily basis.

18. The method according to any one of claims 1 to 17, wherein the monotherapy is administered daily on days 1 to 5. Method or therapeutically effective amount.

19. 20. The method of claim 18, wherein the treatment further comprises an antihistamine, and optionally an analgesic. or a therapeutically effective amount.

20. The combination therapy according to any one of claims 1 to 19, wherein the combination therapy continues for up to 35 treatments. Method or therapeutically effective amount.

21. The method according to any one of claims 1 to 20, wherein the subject is after first-line treatment for metastatic pancreatic adenocarcinoma.

2. A method or a therapeutically effective amount according to any one of claims 1 to 11.

22. 22. The method of claim 21, wherein the first line treatment comprises gemcitabine-based chemotherapy. or a therapeutically effective amount.

23. The method of any one of claims 1 to 21, wherein the metastatic pancreatic adenocarcinoma is unresectable. or a therapeutically effective amount.

24. The method according to any one of claims 1 to 21, wherein the metastatic pancreatic adenocarcinoma is pancreatic ductal adenocarcinoma. or a therapeutically effective amount.

25. 25. The method of claim 24, wherein the metastatic pancreatic ductal adenocarcinoma comprises intraductal papillary mucinous neoplasm. A therapeutically effective amount.

Citation Information

Patent Citations

  • Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin

    WO2017034957A1